Type of animal organ
POPULARITY
Where's the strangest place you can find endo? Can you make more money when you're ovulating? And is it heartburn or a heart attack? In this episode we talk to gynaecological surgeon and endometriosis specialist, Dr Amani Harris and learn the telltale signs of a female heart attack. Sign up to the Well Newsletter to receive your weekly dose of trusted health expertise without the medical jargon. Ask a question of our experts or share your story, feedback, or dilemma - you can send it anonymously here, email here or leave us a voice note here. THE END BITS Follow us on Instagram and Tiktok. All your health information is in the Well Hub. For more information on endometriosis, visit Endometriosis Australia. For more information on periods and a pain and symptom diary, Dr Mariam recommends the Jean Hailes website. For more on heart attack signs and symptoms in women, visit the Heart Foundation. Support independent women’s media by becoming a Mamamia subscriberCREDITSGuest: Dr Amani HarrisHosts: Claire Murphy and Dr MariamSenior Producers: Claire Murphy and Sasha TannockAudio Producers: Scott StronachVideo Producer: Julian Rosario Mamamia acknowledges the Traditional Owners of the Land we have recorded this podcast on, the Gadigal people of the Eora Nation. We pay our respects to their Elders past and present, and extend that respect to all Aboriginal and Torres Strait Islander cultures. Information discussed in Well is for education purposes only and is not intended to provide professional medical advice. Listeners should seek their own medical advice, specific to their circumstances, from their treating doctor or health care professional.Support the show: https://www.mamamia.com.au/mplus/See omnystudio.com/listener for privacy information.
This week Patrick is joined by Paul Wille, Director of Product Development at Abeona Therapeutics. They discuss the use of adeno-associated virus (AAV) as a vector for gene therapy delivery, outline its limitations and benefits, and hone in its potential in the context of genetic eye disorders. Paul also shares his journey from academia to industry and emphasizes the importance of building on existing technologies to advance the field. Additionally, please consider joining us at our first in-person podcast event! We will be hosting a reception during the ASHG Annual Meeting in Denver, CO. The event will be held on the evening of Thursday 7 November. Please submit your information in this form (https://lu.ma/geneticspodASHG) to signify your interest in attending!
Na jednom z nejmenších náměstí u nás - uprostřed obce Tři Studně na Žďársku - je už třicet let každé léto otevřena Malá galerie. Založila ji rodina malíře a grafika Ivana Svatoše, který v ní nabízí své obrázky pražských zákoutí a ulic, ale také Vysočiny i jiných míst.
Hoy hablo con Andrea Ruiz. Conversamos sobre:-Lupron, que es parte de una categoría de medicamentos llamados GnRh que baja tu estrógeno a niveles menopáusicos. -como varios estudios que comparan los medicamentos GnRh con otros medicamentos hormonales muestran que todos ellos proporcionan un alivio similar de los síntomas.-como el Lupron pueden tener efectos secundarios graves, e incluso incapacitantes, a largo plazo que continúan en algunos pacientes mucho después de dejar de tomar el medicamento.Quién es Andrea Ruiz?Andrea es Presidenta de la Asociación de Pacientes con Endometriosis y Adenomiosis del Perú. Hablamos en el episodio 3 sobre la nueva ley de endometriosis en Perú y su importancia para la comunidad de endometriosis en Perú.Para contactar con Andrea:INSTAGRAM @endometriosisperuFACEBOOK: Pacientes Endometriosis Perú. https://www.facebook.com/endometriosisperu¿Quieres más información en español sobre la endometriosis?LUPRON: https://insixteenyears.com/lupron-2/MI PÁGINA WEB: www.endoenloprofundo.comINSTAGRAM: @endo.en.lo.profundo
DEARG: Delivering Endometriosis and Adenomyosis Resources and Guidance
Summary Jen Moore, aka Jen.dometriosis on social media, is an endometriosis and adenomyosis educator, speaker and campaigner. Following her 22 year long battle for a diagnosis, she now helps others suffering with these conditions, as well as working to create change on an institutional level.She has worked with the BBC, NHS, University of Cambridge, and global pharmaceutical companies; as well as contributing to research, books and consulting for national charities. Jen is a UN Women UK delegate for the 68th Commission on the Status of Women, where she is determined to include endometriosis and adenomyosis in these vital and high level discussions.Jen is also the founder of two Endometriosis based research projects. The first, Endo Education, is looking at the current state of medical teaching in the UK when it comes to endometriosis. The second, the They Said What?! project is a deeply personal piece of work, collating the lived experiences of medical misogyny faced by those suffering with the disease. In this episode, Kathleen chats with Jen, about her journey with endometriosis and adenomyosis. They discuss the importance of accurate information and definitions, the impact of misinformation and lack of education, the role of healthcare professionals in education, the hope for change and future generations, and the importance of sharing personal stories and accurate information on social media. Jen shares her experience of upskilling and educating herself on endometriosis and adenomyosis and provides advice for others who want to do the same. This conversation covers topics such as misinformation and media influence, the power of social media, the "They Said What" project, the impact of medical gaslighting, raising awareness for adenomyosis, and the emotional journey of a hysterectomy. It also discusses the complexities of post-surgery pain. Takeaways Be cautious of misinformation and sensationalised headlines in the media and on social media. Stay curious, ask questions, and think critically about the information you come across. The They Said What project aims to document and amplify experiences of medical gaslighting and dismissal in women's healthcare. It highlights the need for change and exposes the widespread issue of medical mistreatment. Adenomyosis is a condition that is often overlooked and misunderstood. More awareness and research are needed to address the impact of adenomyosis on individuals' lives. The emotional journey of a hysterectomy can be complex, and individuals may experience conflicting emotions. It is important to provide psychological support and acknowledge the significance of the choice to undergo a hysterectomy. Post-surgery pain can persist even after a hysterectomy and excision, and additional work may be required to address other pelvic pain generators. It is essential to have realistic expectations and explore all available tools for pain management. Jen's Website https://www.jenmoore.co.uk/ Jen on Instagram https://www.instagram.com/jen.dometriosis/ They Said What Submissions https://www.jenmoore.co.uk/projects/theysaidwhatproject They Said What?! Instagram https://www.instagram.com/theysaidwhatproject/
If you've heard of endometriosis, you may know of a similar condition: adenomyosis. Adenomyosis is the growth of endometrial-like tissue growing into the muscle of your uterus. Adeno can create symptoms that are even more severe and difficult to resolve like pelvic pain and pain with your period. In this episode, I dive into the signs of adenomyosis and how to determine if you are struggling with it. DUTCH Test: https://drbethwestie.com/dutch-hormone-testing/
If you've heard of endometriosis, you may know of a similar condition: adenomyosis. Adenomyosis is the growth of endometrial-like tissue growing into the muscle of your uterus. Adeno can create symptoms that are even more severe and difficult to resolve like pelvic pain and pain with your period. In this episode, I dive into the root cause of adenomyosis and some treatment options. DUTCH Test: https://drbethwestie.com/dutch-hormone-testing/
In this episode of the Proof of Coverage podcast, Sal interviews Maria Lima, the founder of Weaver Labs and the Adeno network. Maria shares the origin story of Weaver Labs and discusses their work in powering lab deployments across Europe. They delve into the innovative technology behind Weaver Labs, including their full-stack modular software platform for scaling wireless networks. Listeners will gain insights into the exciting advancements being made in the field of telecommunications. Follow Maria: @MariaMariuru [00:02:05] Demo or die approach. [00:04:41] Decentralizing telecommunications infrastructure. [00:08:30] Innovation in the telecom ecosystem. [00:09:41] UK's investment in telecoms. [00:14:50] Building a 5G private network. [00:16:20] Using street furniture for network deployment. [00:19:58] Neutron host model explained. [00:23:34] Fixed wireless access trial. [00:26:14] Residential connectivity cost analysis. [00:30:16] Telecom sector funding scarcity. Disclaimer: The hosts and the firms they represent may hold stakes in the companies mentioned in this podcast. None of this is financial advice.
You may be familiar with endometriosis, but this episode is dedicated to a similar condition: adenomyosis. Adenomyosis is the growth of endometrial-like tissue growing into the muscle of your uterus. Adeno can create symptoms that are even more severe and difficult to resolve like pelvic pain and pain with your period. In this episode, I dive into the top 5 symptoms of Adeno and what you can do about it! DUTCH Test: https://drbethwestie.com/dutch-hormone-testing/
Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.06.26.546585v1?rss=1 Authors: Wu, H., Zhou, L.-Y., Jin, C.-X., Wang, W.-X., Song, L., Shin, J.-B., Du, T.-T. Abstract: The MRTF-SRF pathway has been extensively studied for its crucial role in driving the expression of a large number of genes involved in actin cytoskeleton of various cell types. However, the specific contribution of MRTF-SRF in hair cells remains unknown. In this study, we showed that hair cell-specific deletion of Srf or Mrtfb, but not Mrtfa, leads to similar defects in the development of stereocilia dimensions and the maintenance of cuticular plate integrity. We used FACS-based hair cell RNA-seq analysis to investigate the mechanistic underpinnings of the changes observed in Srf and Mrtfb mutants, respectively. Interestingly, the transcriptome analysis revealed distinct profiles of genes regulated by Srf and Mrtfb, suggesting different transcriptional regulation mechanisms of actin cytoskeleton activities mediated by Srf and Mrtfb. Exogenous delivery of calponin 2 using Adeno-associated virus transduction in Srf mutants partially rescued the impairments of stereocilia dimensions and the F-actin intensity of cuticular plate, suggesting the involvement of Cnn2, as an Srf downstream target, in regulating the hair bundle morphology and cuticular plate actin cytoskeleton organization. Our study uncovers, for the first time, the unexpected differential transcriptional regulation of actin cytoskeleton mediated by Srf and Mrtfb in hair cells, and also demonstrates the critical role of SRF-CNN2 in modulating actin dynamics of the stereocilia and cuticular plate, providing new insights into the molecular mechanism underlying hair cell development and maintenance. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC
Wissenschaftler*innen von der Charité und der Medizinischen Universität Innsbruck haben nun die EpiBlok Therapeutics GmbH gegründet, die eine Gentherapie entwickelt, bei der ein Adeno-assoziiertes-Virus das Gen für das Neuropeptid Dynorphin gezielt in Neurone der betroffenen Hirnregion bringt. Ziel ist eine langfristige Unterdrückung von Anfällen, indem die Nervenzellen Dynorphin auf Vorrat produzieren und bei Bedarf ausschütten. Im Interview erklärt Prof. Regine Heilbronn, wie die Gentherapie funktioniert.
Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.04.13.536491v1?rss=1 Authors: Stanton, M. M., Hariani, H. N., Sorokin, J., Taylor, P. M., Modan, S., Rash, B. G., Rao, S. B., Enriquez, L., Quang, D., Hsu, P.-K., Paek, J., Owango, D., Castrillo, C., Nicola, J., Ramkumar, P., Lash, A., Flanzer, D., Shah, K., Kato, S., Skibinski, G. Abstract: Human-derived cortical organoids (hCOs) recapitulate cell diversity and 3D structure found in the human brain and offer a promising model for discovery of new gene therapies targeting neurological disorders. Adeno-associated viruses (AAVs) are the most promising vehicles for non-invasive gene delivery to the central nervous system (CNS), but reliable and reproducible in vitro models to assess their clinical potential are lacking. hCOs can take on these issues as they are a physiologically relevant model to assess AAV transduction efficiency, cellular tropism, and biodistribution within the tissue parenchyma, all of which could significantly modulate therapeutic efficacy. Here, we examine a variety of naturally occurring AAV serotypes and measure their ability to transduce neurons and glia in hCOs from multiple donors. We demonstrate cell tropism driven by AAV serotype and hCO donor and quantify fractions of neurons and astrocytes transduced with GFP as well as overall hCO health. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC
April is Adenomysosis Awareness Month and the NCMP wanted to take time to discuss the disease in further detail. Betsy also reflects on her Adeno diagnosis and hysterectomy. Thank you for tuning in. Please let us know if you have any questions! Follow up on IG @notchamommapod. Make sure to like, share, and leave us a comment!
Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.02.21.529451v1?rss=1 Authors: Gleichman, A. J., Kawaguchi, R., Sofroniew, M. V., Carmichael, S. T. Abstract: Astrocytes, one of the most prevalent cell types in the central nervous system (CNS), are critically involved in neural function in both health and disease. Genetically manipulating astrocytes is an essential tool in understanding and affecting their roles. Adeno-associated viruses (AAVs) enable rapid genetic manipulation; however, astrocyte specificity of AAVs can be limited, with high off-target expression in neurons and sparsely in endothelial cells. Here, we report the development of a cassette of miRNA targeting sequences (4x6T) which triggers transgene degradation specifically in neurons and endothelial cells. 4x6T increases astrocytic expression of Cre with a viral reporter from less than 50% to greater than 99% in four tested serotypes in mice, and confers astrocyte specificity in two inducible forms of Cre; Dre; and reporters. We also present empty vectors to add 4x6T to other cargo, independently and in Cre/Dre-dependent forms. This toolbox of AAVs provides a way to rapidly manipulate astrocytes throughout the CNS. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC
This episode is unlike anything I have done before... going deep & personal with my best friend and cousin on her wild, brave & incredible journey. We come from similar genetics (mothers are sisters), and we share some of the same health issues BUT Megan also has a totally different story to me when it comes to Endo, Adeno, childbirth, pregnancy, stress, training and mental health. I would love to hear your thoughts on this episode, as I am certain you are going to relate to so many of the things we chat about! If you relate to Megan's story please reach out, as you shouldn't have to walk this journey alone! Big love to you if your struggling and big love to Megan for being brave, being a mother, and for always striving to find an answer when life continues to throw her curve balls. We cover: Training and your health Endometriosis & Adenomyosis Heavy, painful periods Mental health Two sets of twins Depleted bodies Immune dysfunction Trauma Bloating & gut issues Food intolerances And more! LINKS TO SHERADYN: Assess your gut health in 3min HERE Follow me on Instagram HERE. Join my Private Facebook group HERE. Check out my website HERE See omnystudio.com/listener for privacy information.
Đậu mùa khỉ, Covid-19, Adeno và mới nhất là Cúm gia cầm xuất hiện… đã và đang uy hiếp sức khỏe cộng đồng, đặc biệt là các bệnh nhi.
- Thưa quý vị và các bạn! Trước tình hình số lượng ca mắc virus Adeno phải nhập viện tăng cao, ngành y tế yêu cầu các cơ sở khám chữa bệnh bố trí đủ giường bệnh, nhân lực, phương tiện, trang thiết bị, vật tư để chẩn đoán và điều trị người bệnh nhiễm Adenovirus. Đồng thời thực hiện tốt công tác phân luồng, kiểm soát nhiễm khuẩn, phòng chống lây nhiễm trong các cơ sở khám chữa bệnh. Vậy Andeno virus cần nhận biết, điều trị, phòng ngừa ra sao? Xin mời quý vị và các bạn cùng nghe --- Support this podcast: https://anchor.fm/vov1sukien/support
- Tiếp tục các hoạt động của Đoàn Việt Nam tham dự Phiên thảo luận cấp cao Đại hội đồng Liên hợp quốc Khoá 77 tại New York, Hoa Kỳ, Phó Thủ tướng Thường trực Phạm Bình Minh tham dự Hội nghị về Tác động của phát triển bền vững năm 2022 do Diễn đàn Kinh tế thế giới tổ chức - Ủy ban TVQH cho ý kiến về dự thảo Kế hoạch giám sát chi tiết và đề cương các báo cáo của Đoàn giám sát của Ủy ban Thường vụ Quốc hội về “Việc thực hiện chính sách, pháp luật về phát triển năng lượng giai đoạn 2016 – 2021 - Bộ Y tế họp khẩn tìm cách ứng phó dịch do virus Adeno khiến hàng nghìn trẻ nhập viện - Bão Noru sẽ vào biển Đông từ đêm mai, với sức gió cấp 9-10. Ban chỉ đạo quốc gia về Phòng, chống thiên tai yêu cầu các tỉnh từ Quảng Ninh đến Bình Thuận khẩn trương kêu gọi và hướng dẫn tàu thuyền nhanh chóng thoát ra khỏi vùng nguy hiểm - Hội nghị Bộ trưởng Công nghiệp, Thương mại và Đầu tư G20 kết thúc sau 3 ngày họp tại Bali, Indonesia, nhất trí về 6 chương trình nghị sự ưu tiên để giải quyết các thách thức thương mại, thúc đẩy sự phục hồi kinh tế toàn cầu hậu đại dịch - Chứng khoán toàn cầu lao dốc sau quyết định tăng lãi suất của các ngân hàng trung ương Chủ đề : bộ y tế, họp khẩn, trẻ nhập viện --- Support this podcast: https://anchor.fm/vov1thoisu0/support
- Sáng 22/9, UB TVQH cho ý kiến vào Dự án Luật đất đai (sửa đổi). Đây là dự án Luật lớn, có tác động sâu sắc tới nhiều mặt của đời sống KT-XH của đất nước. - Hơn 300 trẻ nhập viện do virus Adeno, Bộ Y tế yêu cầu tăng cường giám sát, không để bùng dịch. - Khai mạc Lễ hội truyền thống tưởng niệm 154 năm Anh hùng dân tộc Nguyễn Trung Trực hy sinh. - Tổng thống Mỹ Joe Biden chỉ trích Nga trong cuộc khủng hoảng Ucraina. - Dư luận Nga ủng hộ việc Tổng thống Vladimir Putin ký sắc lệnh về động viên một phần quân đội - Cục Dự trữ Liên bang Mỹ (FED) công bố thêm một đợt tăng lãi suất mạnh nhằm hạ nhiệt lạm phát. -Bình luận:“Cán bộ giữ gìn liêm sỉ để cuộc đấu tranh phòng chống tham nhũng thành công”. Chủ đề : 300 trẻ nhập viện, virus Adeno, bùng dịch --- Support this podcast: https://anchor.fm/vov1thoisu0/support
Việt Nam báo động số ca nhập viện và tử vong tăng, đặc biệt nơi trẻ em, vì virus adeno. Virus adeno là gì, gây bệnh gì? làm sao tránh, có cách điều trị không? Cùng tìm hiểu với BS Nhi khoa Quỳnh Kiều.
- Thủ tướng Chính phủ Chủ trì Hội nghị với doanh nghiệp, hiệp hội doanh nghiệp đầu tư nước ngoài. - Chủ tịch Quốc hội Vương Đình Huệ kiểm tra công tác chuẩn bị tổ chức Diễn đàn Kinh tế - Xã hội Việt Nam 2022. - Gần 1 nghìn tỷ đồng vốn đầu tư công tạm ứng bị biến thành “nợ khó đòi” – câu chuyện xảy ra tại tỉnh Đắc Lắc. - Lô sầu riêng đầu tiên của Việt Nam hôm nay lên đường chính thức xuất khẩu chính ngạch sang Trung Quốc. - Tổng thống Nga Putin kêu gọi châu Âu dỡ bỏ các lệnh trừng phạt để mở đường ống dòng chảy khí đốt phương Bắc 2. - Sập mỏ vàng vùi lấp 20 người sau sự cố sạt lở đất tại Indonesia. Chủ đề : Nga, Khí đốt, virus Adeno, sầu riên --- Support this podcast: https://anchor.fm/vov1thoisu0/support
Nick is a fellow Endo and Adeno warrior. She has survived infertility and is now embracing life post a hysterectomy. Most importantly, she a part of the Infertile Myrtles and has became a close friend to the pod. Follow her on IG @ourstoryunfolding. Like, share, and follow us on IG @notchamommapod and tag us in the movement challenge with the hashtag #movementmedicine. DM any gentle corrections or email us at notchamommapod@gmail.com. Anchor listeners - leave us voice messages at https://anchor.fm/notchamommapod/message.
In this episode, Nigerian actor, Nse Ikpe-Etim talks about being diagnosed with adenomyosis, a medical condition that affects the fertility of women. She discusses her journey to healing, and getting a hysterectomy. To get inside information about every episode, subscribe to our newsletter here. You will get behind-the-scenes information from Aisha Salaudeen, and find out what the rest of the team is up to. “I Like Girls” is Aisha Salaudeen, Afolabi Adekaiyaoja, Samiat Alamutu, Dorcas Ohwofasa, Dooski, Mo Isu, Ruth Olurounbi and Banggz. This episode is sponsored by Piggyvest.
You've probably heard of endometriosis, but adeno is what we're calling endo's lesser known evil cousin. It's a hell of a chronic illness, and for Adenomyosis Awareness Month we're bringing you up to speed on what it is, why it often gets confused with endo, and how to cure it. For questions or topic suggestions email thehookup@abc.net.au or dm us @triplejthehookup https://www.instagram.com/triplejthehookup
You've probably heard of endometriosis, but adeno is what we're calling endo's lesser known evil cousin. It's a hell of a chronic illness, and for Adenomyosis Awareness Month we're bringing you up to speed on what it is, why it often gets confused with endo, and how to cure it. For questions or topic suggestions email thehookup@abc.net.au or dm us @triplejthehookup https://www.instagram.com/triplejthehookup
You've probably heard of endometriosis, but adeno is what we're calling endo's lesser known evil cousin. It's a hell of a chronic illness, and for Adenomyosis Awareness Month we're bringing you up to speed on what it is, why it often gets confused with endo, and how to cure it.For questions or topic suggestions email thehookup@abc.net.au or dm us @triplejthehookuphttps://www.instagram.com/triplejthehookup
You've probably heard of endometriosis, but adeno is what we're calling endo's lesser known evil cousin. It's a hell of a chronic illness, and for Adenomyosis Awareness Month we're bringing you up to speed on what it is, why it often gets confused with endo, and how to cure it.For questions or topic suggestions email thehookup@abc.net.au or dm us @triplejthehookuphttps://www.instagram.com/triplejthehookup
In this episode I chat with Sam Murray from Empowered Holistic Counselling & Wellness. A great episode for those men in your life too, to understand a bit more about Endo and how is not just about your period or 'that time of the month'.We had a great in-depth chat about being your own health advocate, learning about your intuition, using your voice and if something doesn't feel right to keep going until you find the answers that are right for you and sit right with you. Sam has been living with Endo and Adeno and how it impacts her entire life. She speaks about her journey from 10yo and how she navigated and has dealt with things as they have come up, and the changes she has made to her life, career and health.What does a holistic health approach look like when 'pushing through' doesn't work.....Tune in to find out more! If you would like to connect with Sam, head over on Instagram @empowered_holistic_counselling + @empowered_skincare_rangeSupport the show (https://paypal.me/studiochatpodcast?country.x=AU&locale.x=en_AU)
Hey LTP fam! Welcome back for a brand spanking new ep of LTP!Today's solo episode is part 2 of all about adenomyosis! With it being adeno awareness month currently, I would it would be a great opportunity to share all about adeno and answer some questions from the LTP fam! Things I mentioned in the ep:Is it Endo, Adeno or PCOS blog - Let's Talk, Period.1:1 Mentoring with Isabella Harada, T. et al. (2016). The Impact of Adenomyosis on Women's Fertility. Obstetrical and Gynaecological Survey, 71(9), 557-568. If you haven't got your ticket for our online textured paint and sip yet, get on it! Tickets are $65 and it is going to be SUCH a fun evening!! Get your ticket here If you want to keep updated with all things Let's Talk, Period. you can follow us on Instagram at @letstalkperiodau. Don't forget we also have our Let's Talk, Period. Community on facebook. It's the place for people with endo, adeno, pcos or chronic illnesses to ask questions, get support and connect with others who get it! You can join here!Let's Talk, Period. is an independent podcast, so if you did enjoy this episode and want to support the show, it would be amazing if you could follow on apple podcasts and leave a rating and review, or if you're listening along on spotify, you can follow the show and leave a rating!If you want to help grow the Let's Talk, Period. community, you could share this episode with a friend or anyone who you think might enjoy our show or even share that you're listening on your instagram grid or stories! This really helps to find new listeners and build the beautiful LTP podcast community!Your host is Isabella Gosling (@i_gosling)
Hey LTP fam! Welcome back for a brand spanking new ep of LTP!Today's solo episode is all about adenomyosis! With it being adeno awareness month currently, I would it would be a great opportunity to share all about adeno and answer some questions from the LTP fam! Things I mentioned in the ep:Is it Endo, Adeno or PCOS blog - Let's Talk, Period.Frendo AppIf you haven't got your ticket for our online textured paint and sip yet, get on it! Tickets are $65 and it is going to be SUCH a fun evening!! Get your ticket here If you want to keep updated with all things Let's Talk, Period. you can follow us on Instagram at @letstalkperiodau. Don't forget we also have our Let's Talk, Period. Community on facebook. It's the place for people with endo, adeno, pcos or chronic illnesses to ask questions, get support and connect with others who get it! You can join here!Let's Talk, Period. is an independent podcast, so if you did enjoy this episode and want to support the show, it would be amazing if you could follow on apple podcasts and leave a rating and review, or if you're listening along on spotify, you can follow the show and leave a rating!If you want to help grow the Let's Talk, Period. community, you could share this episode with a friend or anyone who you think might enjoy our show or even share that you're listening on your instagram grid or stories! This really helps to find new listeners and build the beautiful LTP podcast community!Your host is Isabella Gosling (@i_gosling)
It's time for another little bonus ep for endo awareness month! Today's bonus episode is with Aroha Liebhart. Aroha is an endo, adeno and PCOS sufferer and has had quite the tumultuous journey to diagnosis. She is passionate about making a difference in the lives of others, and has actively committed to advocate for others. Later this year will be embarking on a three day trek in WA to raise money for endometriosis research. We chat on: Aroha's endo story and how she finally got diagnosed with endo, adeno and PCOSWhy she feels there is still such a delay to diagnosis, even in 2022Challenges and considerations Aroha has had to make to accommodate her illnessesWhat her chronic illnesses have given her All about the trek she is doing later in the year to raise money for endo researchPlus so much more! Thank you so much for listening to this episode of Let's Talk, Period. with Aroha. If you want more from her, you can follow her on instagram @ladyb_16 and you can find out more about her upcoming trek, as well as donate here . If you want to keep updated with all things Let's Talk, Period. you can follow us on Instagram at @letstalkperiodau. Don't forget we also have our Let's Talk, Period. Community on facebook. It's the place for people with endo, adeno, pcos or chronic illnesses to ask questions, get support and connect with others who get it! You can join here!Let's Talk, Period. is an independent podcast, so if you did enjoy this episode and want to support the show, it would be amazing if you could follow on apple podcasts and leave a rating and review, or if you're listening along on spotify, you can follow the show and leave a rating!If you want to help grow the Let's Talk, Period. community, you could share this episode with a friend or anyone who you think might enjoy our show or even share that you're listening on your instagram grid or stories! This really helps to find new listeners and build the beautiful LTP podcast community!Your host is Isabella Gosling (@i_gosling)
On this episode, we have returning guest Dr. Abby McElroy who previously was a guest on the Hypermobility Happy Hour discussing EDS in animals. Today, she returns with her principal investigator Dr. Heather Gray-Edwards to discuss the exciting new research they have been working on. Dr. Gray-Edwards is an assistant professor of Radiology at the University of Massachusetts' Chan Medical School and is a member of the Horae Gene Therapy Center. Much of her research has been focused on evaluating therapeutic interventions in testing novel Adeno-associated viral vectors and delivery routes using both biochemical and molecular biology techniques, as well as in vitro evaluation like neurological examinations, MRIs, and electrodiagnostics of GM1 and GM2 gangliosidosis cats. Dr. McElroy is a doctoral student who previously received her Doctor of Veterinary Medicine degree from Tufts University in 2017. She further obtained a master's degree from Michigan State University in 2018 which focused on the characterization of neurological abnormalities in an equine model of Ehlers-Danlos syndrome. From 2018 to 2021, Dr. McElroy was a Postdoctoral Research Associate in the Department of Neurosurgery at Rhode Island Hospital and the Medical School of Brown University where she studied tethered cord syndrome and myodural bridge dysfunction in patients with Ehlers-Danlos Syndrome. In her current position at the Gray-Edwards laboratory at the University of Massachusetts' Chan Medical School focuses on the development of gene therapy for Ehlers-Danlos syndromes and multisystemic smooth muscle dysfunction syndrome (related to the ACTA2 mutation). Abby also has two cats and two dogs and one of her cats has Ehlers-Danlos syndrome and is a bit of a social media star in his own right (his name is Reed and you can follow him at reed_eds)
Podcast Editor, Tracy Carlson, interviews authors Basel Assaf and Julie Hutt to discuss the article, "Scientific and Regulatory Policy Committee Points to Consider: Nonclinical Research and Development of In Vivo Gene Therapy Products, Emphasizing Adeno-Associated Virus Vector" which can currently be found in Vol 50, Issue 1, 2022 of Toxicologic Pathology. Click here to read the article
Adeno-associated viral vectors, or AAVs, are the tiny shells of viruses. And today they are the most common vessels for delivering gene-based therapies. In this episode, we'll launch into the past, present, and future of AAVs. Imagine a rocket ship blasting off from Earth with cargo bound for a distant space station, and you have a pretty good idea what adeno-associated viral vectors are all about. But instead of ferrying hardware and supplies, AAVs carry genes.It's an achievement nearly six decades in the making. That might seem like a long time to tinker with something smaller than the tiniest single-celled organism. But just like building a rocket ship destined for the deep reaches of space, the development of AAV vectors required patience, persistence, and a few leaps of faith.In the era before DNA sequencing and gene cloning, scientists in the 1960s realized that adeno-associated viral vectors could be a window into understanding genetic variations in viruses – and eventually other organisms, too.The fact that AAVs were immunologically distinct from other viruses made them curious things.So in the 1970s, AAV research took off in three directions. One determined that the simple AAV DNA could be rewritten and edited in a lab. The second found that although these small viruses can infect humans, they don't replicate without a “helper virus” (such as adenovirus). In the absence of another virus, they remain latent, and appear to be of little threat to human health. The third investigated whether AAVs could become vectors for transferring genes from one organism to another. This all culminated in 1978, when the first cloned AAV was generated and was successfully transferred to a cell of the E. coli bacterium, where it produced 50 new colonies of AAVs.So now we had proof that adeno-associated viruses could be artificially produced, that theycould be hollowed out and filled with other genetic material, and that they could potentially bea vector for delivering genes without harming their new host.By the 1980s, we had the capability to build lots of viral rocket ships and fill them with genetic cargo, we just needed a destination to send them. Enter the burgeoning field of gene therapy, with its focus on developing treatments for genetic diseases like cystic fibrosis, hemophilia B, Parkinson's, and more.Research has continued and today, adeno-associated viral vectors are a mainstay of gene therapy development. While progress is necessarily slow, gene therapy is a science that is aiming for the stars. And with AAV vectors, they are now within our reach.For more education on gene therapy, visit www.genetherapynetwork.com.
Hey gorgeous people, hope you're having a beautiful Wednesday and are hyped for another LTP ep! Today's episode is with Carla Anita Mattiazzo. Carla has been gracing the stages of the world for over 30 years, having studied five different performing arts programs and vocal training since age 12. She has been performing cabaret since 2010, and has had multiple shows in the Adelaide Fringe Festival. Carla's show The Catchelorette won the Best Cabaret Weekly award, had rave reviews and sell out shows! This year she is back with a new show, PERIOD ‘ four seasons, one cycle', focused on the menstrual cycle, social justice and period poverty. We chat on: Carla's experiences with periods and period pain growing up Blocking out pain and continuing on in performing arts and the classroom, as a teacherWhat led her to create PERIOD. and the importance behind itThe process of developing and creating a show from start to finish What to expect when coming to see PERIOD. Plus so much more! Thank you so much for listening to this episode of Let's Talk, Period with Carla Anita Mattiazzo. If you want more from Carla, you can follow her on instagram @carlasconfessionalcabaret. Carla's show, PERIOD. runs from 22 Feb - 6 March as part of the Adelaide Fringe. You can get tickets for in person or online watch at home performances here. $1 from each ticket sale goes towards a charity who helps bleeders in need. Also! If you want to join in on some endo awareness fun next month, join me for our LTP online trivia event! Tickets are just $10 and you can play in a team or solo, and some fabulous prizes are on offer. You can get your ticket here.If you want to keep updated with all things Let's Talk, Period. you can follow us on Instagram at @letstalkperiodau. Don't forget we also have our Let's Talk, Period. Community on facebook. It's the place for people with endo, adeno, pcos or chronic illnesses to ask questions, get support and connect with others who get it! You can join here!Let's Talk, Period. is an independent podcast, so if you did enjoy this episode and want to support the show, it would be amazing if you could follow on apple podcasts and leave a rating and review, or if you're listening along on spotify, you can follow the show and leave a rating!If you want to help grow the Let's Talk, Period. community, you could share this episode with a friend or anyone who you think might enjoy our show or even share that you're listening on your instagram grid or stories! This really helps to find new listeners and build the beautiful LTP podcast community!Your host is Isabella Gosling (@i_gosling)
Hey, hi, hellooo beautiful soul! Welcome back for another ep of LTP!Today's episode is with Amy Marks. Amy is an endometriosis sufferer, being officially diagnosed in 2020, after experiencing pain and symptoms for over 8 years. She is now studying part time and recently was successful in obtaining the Disability Support Pension. We chat on: Amy's experience being diagnosed with endo in 2020What she would say to someone who has just been diagnosed with endoThe most challenging aspects of endometriosis and how it impacts her life Tips for studying with a chronic illness Amy's experience being able to get the Disability Support Pension and her advice to someone going through that processI also do a more in depth dive into the Disability Support Pension and the process behind it, including the income and assets test, medical rules and non-medical rules, income limits, evidence needed and the medical assessment to be granted the DSP. I also talk through what happens if you're unsuccessful and what to do next. I mention a few links in the ep, so they're down below for you to check them out, should you wish! DSP Info + Links DSP Pre-Claim Eligibility CheckNon-Medical Rules Medical Rules How Claim is Assessed How to Claim done online or will need:SA466 FormIncome and Assets Form Consent to Disclose Medical Information FormDSP Medical Evidence ChecklistSupporting Documents Thank you so much for listening to this episode of Let's Talk, Period with Amy Marks. If you want to keep updated with all things Let's Talk, Period. you can follow us on Instagram at @letstalkperiodau. Don't forget we also have our Let's Talk, Period. Community on facebook. It's the place for people with endo, adeno, pcos or chronic illnesses to ask questions, get support and connect with others who get it! You can join here!Let's Talk, Period. is an independent podcast, so if you did enjoy this episode and want to support the show, it would be amazing if you could follow on apple podcasts and leave a rating and review, or if you're listening along on spotify, you can follow the show and leave a rating!If you want to help grow the Let's Talk, Period. community, you could share this episode with a friend or anyone who you think might enjoy our show or even share that you're listening on your instagram grid or stories! This really helps to find new listeners and build the beautiful LTP podcast community!Your host is Isabella Gosling (@i_gosling)
Happy 2022 LTP fam! Welcome back to season 4 of Let's Talk, Period. I am so excited to be back and have missed putting out content and being in your ears! Today's episode is with me! I talk all about my experience getting diagnosed with endo and adeno and the journey that it took for this to happen. I chat on: My first period experienceWhen I noticed something was wrongEmbarrassing period stories How many specialists it took to get someone to listen to me What it was like to go through this experienceWhat helped me along the way How I'm managing nowThank you so much for listening to this episode of Let's Talk, Period with me (Isabella Gosling). If you want to follow my personal instagram, it's @i_gosling. If you want to keep updated with all things Let's Talk, Period. you can follow us on Instagram at @letstalkperiodau. Don't forget we also have our Let's Talk, Period. Community on facebook. It's the place for people with endo, adeno, pcos or chronic illnesses to ask questions, get support and connect with others who get it! You can join here!Let's Talk, Period. is an independent podcast, so if you did enjoy this episode and want to support the show, it would be amazing if you could follow on apple podcasts and leave a rating and review, or if you're listening along on spotify, you can follow the show and leave a rating! If you want to help grow the Let's Talk, Period. community, you could share this episode with a friend or anyone who you think might enjoy our show or even share that you're listening on your instagram grid or stories! This really helps to find new listeners and build the beautiful LTP podcast community!Your host is Isabella Gosling (@i_gosling)
Let's talk about chronic illness and finding ways to enjoy the holidays without risking flare ups! The Not Cha Momma Pod shares our top tips! Like, share, and follow us on IG @notchamommapod and tag us in the meditation challenge with the hashtag #movementmedicine. DM any gentle corrections or email us at notchamommapod@gmail.com. Anchor listeners - leave us voice messages at https://anchor.fm/notchamommapod/message.
In episode 5, Heather interviews Hannah Krumreich, who's battled Endo and Adeno for 13 years! She hasn't been able to tell her story until now, and she tells all about her battle with illness, sex, body image, suicide, doctors, surgery after surgery, and finding a way to move from hopeless to hopeful. Hannah does not preach being positive; instead she encourages others to find support, find themselves, and find love, but not where you'd think! In this episode you'll learn: -What is Endometriosis & Adenomyosis; key difference between the two -On overage, how long it takes to get a diagnosis and why -How there is no prevention, no real screening, and no cure -How she learned to deal with chronic illness and how unhealthy it was -What giving up looks like, but how to decide to fight stronger, advocate for yourself and literally move through pain -What it's like viewing sex through the eyes of Endo & Adeno and how she is still figuring this out Feel free to contact Hannah with questions: Instagram @hannah_runs26.2 Email: hannah.krumreich@gmail.com Heather is looking for individuals and couples to tell your story on her podcast! Here is how you can get in touch with her! Instagram: @Sexcess_Story Facebook: Heather DeKeyser-Smith Email: heather.hopetherapeutics@gmail.com
Hey lovely people! I hope you're having a super fab week and are excited for a new ep! Today's episode is with Dr Mikayla Couch. Dr Mikayla Couch is an Obstetrics and Gynaecology Registrar and proud Bundjalung woman who has a keen interest in Indigenous Women's Health. She is passionate about making a difference in the lives of women through providing and advocating for excellent medical care. Through her Instagram account @dr.aboriginal.woman, she continually uses her presence online to provide commentary and create change in the health space. Dr Mikayla is empathetic and strives to provide person centred care through lived experience, suffering from PCOS herself.We chat on: How she keeps herself accountable with goals Mikayla's experience with periods growing up and lack of understanding about periodsBeing diagnosed with PCOS at 27 and coming to terms with that diagnosisWhat drove Mikayla to become a doctor Challenges Aboriginal and Torres Strait Islander people face in healthcareThe impact that the pandemic has had on fertility, fertility treatments and finding a partner The optimal age for egg freezing Thank you so much for listening to this episode of Let's Talk, Period with Dr Mikayla Couch, Obstetrics and Gynaecology Registrar. If you want more from Dr Mikayla, you can follow her on instagram at @dr.aboriginal.woman. If you want to keep updated with all things Let's Talk, Period. you can follow us on Instagram at @letstalkperiodau.ALSO! Join me for the very first Let's Talk, Period. LIVE event on Friday 5 November in Brisbane! Tickets are super limited so book yours ASAP! As a LTP listener, you can use code LTPFAM for $5 off your ticket! Get yours HERELet's talk period is an independent podcast, so if you did enjoy this episode and want to support the show, it would be amazing if you could 'subscribe' on apple podcasts and leave a rating and review, or if you're listening along on spotify, you can 'follow' the show! If you want to help grow the Let's Talk, Period. community, you could share this episode with a friend or anyone who you think might enjoy our show or even share that you're listening on your instagram grid or stories! This really helps to find new listeners and build the beautiful LTP podcast community!Your host is Isabella Gosling (@i_gosling)
Diagnosed at 41, Endo Champion Amanda Waaldyk joins Ellie Angel-Mobbs to discuss her story living with endometriosis and adenomyosis.
My guest today is Sarah Clark, a health and life coach from Fab Fertile in Canada. In this episode we talk about male fertility. Sarah was 28 years old, when she received a diagnosis of premature ovarian failure. She accepted the diagnosis and had both her children through in vitro fertilization. Years later she realized the root cause of her infertility was a food intolerance. She is a certified life coach with accreditation from the International Coaches Federation and a health coach with training from the Institute for Integrative Nutrition. She is the author of Fabulously Fertile - Supercharge your Fertility Naturally, Fabulously Fertile Cookbook and Fertility Preparation Program. Her fertility coaching program, which includes functional lab testing, supports couples to make diet and lifestyle changes that dramatically improve the chances of a healthy pregnancy and baby! On her Get Pregnant Naturally Podcast she shares that with functional medicine and natural fertility solutions we can eventually reverse infertility. In this episode we talk about: Her own fertility journey with premature ovarian failure and how she was rushed into IVF and egg donation. The importance of reviewing male fertility when trying to conceive Key things that matter with male fertility How functional reference ranges can be used to look understand sperm and overall health How male fertility can be affected by environmental toxins Common health themes that affect male fertility Importance of lifestyle factors like sleep, work and exercise How men often deal or feel with infertility (male and female factor) Emotional support tips for both men and women Nutrition and lifestyle improvements such as environmental exposure The need to find your “love language” and personal needs Recommended supplements and testing for sperm and overall health How the Fab Fertile practitioners use functional medicine to help couples get pregnant Finally, I share what I am working on at the moment and what I will be releasing soon and in the coming months. If you want to be the first to know, then make sure you are on my mailing list: https://endofertilityspecialist.com/endo-fertility-news-mailing-list/ So this is the final episode of Season 2, and there will now be a bit of a break. Season 3 will be out in the New Year. CAN I ASK YOU a FAVOUR? Could you please LEAVE A RATING AND A REVIEW – as this helps spread the love to other women in need. Thank you! Check out my posts on Instagram (@endofertilityspecialist.com) and facebook (@endofertilityspecialist.com). Today's episode is sponsored by the Endo Fertility Resource Library where you can get 3 FREEBIES: E-Book: 5 Things I Learnt to Drop My Pain & Optimise My Fertility, Your Guide to Super Sperm 88 Ways I Dropped My Pain and Got Pregnant ----- Lizzie is a certified nutrition and health coach using a functional and integrative approach, holistic massage therapist, Endometriosis and Adenomyosis sufferer and mother of one. Lizzie works with women with Endo and Adeno to help them find a way to get back to a healthy fertile cycle through her 1:1 coaching programmes. Find out more at endofertilityspecialist.com.
Hellooooo gorgeous people! Today's episode is with the incredibly strong Tamika Nacson, or you may know her as performing artist XIRA. Tamika is an EDM and Pop singer and songwriter with over 20 million streams worldwide. Under the artist name XIRA, Tamika has featured on songs with American DJ 3LAU (Justin Blau) and EDM heavyweight Nicky Romero; and has a new one out in October with Audien. Tamika suffers from endometriosis and after an emergency laparoscopy for an ovarian torsion and PID in 2017, Tamika turned her focus away from performing live and more towards songwriting and recording (things she can do in her own time, in the comfort of her trackies, with a heat pack close by at all times). Chronic illness forced her to reassess and change paths (now working with her chronic illness and not against it) but it has worked out better than ever imagined.We chat on: Tamika's journey to diagnosis for endometriosis in 2010What it was like to need emergency surgery for an ovarian torsionThe decision to pivot away from live performance and the feelings associatedHow Tamika's uses her chronic illnesses in her art as a songwriter The relief Tamika has found with being able to access a disability parking permitHow Tamika deals with people who think she doesn't 'look sick'Plus so much moreDisability Parking Permit Info: QLD NSWACTVICSATASWANTThank you so much for listening to this episode of Let's Talk, Period with Tamika Nacson. If you want more from Tamika, you can follow her on instagram at @xiramusic and listen to her music on Spotify. If you want to keep updated with all things Let's Talk, Period. you can follow us on Instagram at @letstalkperiodau.ALSO! Join me for the very first Let's Talk, Period. LIVE event! They are super limited so book yours ASAP! Also as a LTP listener, you can use code LTPFAM for $5 off your ticket! Get yours HERELet's talk period is an independent podcast, so if you did enjoy this episode and want to support the show, it would be amazing if you could 'subscribe' on apple podcasts and leave a rating and review, or if you're listening along on spotify, you can 'follow' the show! If you want to help grow the Let's Talk, Period. community, you could share this episode with a friend or anyone who you think might enjoy our show or even share that you're listening on your instagram grid or stories! This really helps to find new listeners and build the beautiful LTP podcast community! Your host is Isabella Gosling (@i_gosling)
Happy Wednesday lovely LTP fam! After a week off, it's so great to be back with a brand new ep! What better way to cap off PCOS Awareness Month than with today's episode, with the amazing Ebony Crameri! Ebony is an Accredited Practising Dietitian and credentialed fertility & prenatal dietitian with 12 years clinical experience as a dietitian. Ebony has a special interest in nutrition for fertility, PCOS and endometriosis who provides online consultations to women across Australia and internationally. Ebony's interest in fertility nutrition first developed after her own struggles with infertility and pregnancy losses. Ebony has turned her journey from infertility to motherhood into her passion and created her online nutrition practice to help women to support their reproductive and hormone health as well as optimise their diet for fertility. We talk on: What led Ebony to become a dietitianWhy birth control is so often prescribed for PCOSEbony's approach when working with people who have PCOSThe role of insulin resistance, low progesterone and elevated cholesterol in PCOSHow to support your body to regulate your cycle and promote consistent ovulationEbony's top three tips for navigating a new diagnosis of PCOSPlus so much more!Thank you so much for listening to this episode of Let's Talk, Period with Ebony Crameri, Accredited Practising Dietitian and Nutritionist. If you want more from Ebony, you can follow her on instagram at @hormone.nutrition or head to her website for more info on the services she provides, you can do this If you want to keep updated with all things Let's Talk, Period. you can follow us on Instagram at @letstalkperiodau.Let's talk period is an independent podcast, so if you did enjoy this episode and want to support the show, it would be amazing if you could 'subscribe' on apple podcasts and leave a rating and review, or if you're listening along on spotify, you can 'follow' the show! If you want to help grow the Let's Talk, Period. community, you could share this episode with a friend or anyone who you think might enjoy our show or even share that you're listening on your instagram grid or stories! This really helps to find new listeners and build the beautiful LTP podcast community! Your host is Isabella Gosling (@i_gosling)
Helloooooo lovely people! I'm so excited to share this new ep with you! Today's episode is with the incredibly strong Krystle, founder of @herwithendo and endometriosis and adenomyosis advocate. Krystle started her instagram account in 2018, after her endometriosis diagnosis. For years she wondered what was wrong with her body, and had to continually fight to receive answers and adequate treatment for her pain and symptoms. She has cultivated a following for speaking openly about her experiences with endo and adeno, but also mental health and life as a mum who is also chronically ill. We talk on: How Krystle knew something was wrong and her tumultuous journey to be diagnosed with endoWhat it feels like to finally receive that diagnosis after years of being told nothing's wrong The physical and mental impacts of undergoing over 60 surgical procedures in the last four years and helpful tips for hospitalHow a sacral nerve stimulator has assisted Krystle with bladder and bowel controlWhat it's like being a mum who is chronically ill and the challenges she facesThank you so much for listening to this episode of Let's Talk, Period. with Krystle, founder of Her with Endo. If you loved hearing from Krystle and want more, you can find her on Instagram at @herwithendo. If you want to keep updated with all things Let's Talk, Period. you can follow us on Instagram at @letstalkperiodau.If you want to chat with like-minded people all about the ep today, you NEED to join our Let's Talk, Period. Podcast Community! You can join here.Also a MASSIVE shoutout to today's sponsor How We Roll Co.! You can shop their 100% organic and sustainable tampons designed in collaboration with Australian Artist Brook Gossen now! Do some good for your body, the earth and others in need as How we Roll Co. are donating one box for every ten sold to the Women's and Girls Emergency Centre, who support those affected by domestic violence. Shop here! Your host is Isabella Gosling (@i_gosling)
Happy Wednesday beautiful souls, and helloooooo if you're new here! Today's episode is with the incredible Tegan Scates, industry leader and founder of High on Hemp. Tegan's journey within the Australian hemp industry commenced in 2014 which subsequently lead her to the creation of High on Hemp. High on Hemp was created with one goal in mind, to educate and raise awareness of sustainability, and how hemp can change the way we live and the environment we live in. Through High on Hemp, Tegan aims to challenge the stigma associated with cannabis and showcasing hemp as the natural, raw and rich resource it is. Through Tegan's desire to play a key role within the industry and passion to educate those living in Australia on the insights and knowledge she has from her networks and extensive global travel encompassing hemp and cannabis has allowed her to create a community which focuses on education and advocacy. Since 2017, Tegan has been working with leaders across the globe through extending High on Hemp to also be Australia's first cannabis creative agency. We chat on;How Tegan got into the hemp industry initially Why Tegan started High on Hemp and the transition from sharing hemp products online, to advocacy and news around the whole cannabis productSome of the biggest misconceptions around medicinal cannabis What some of the key issues are when it comes to black market productsThe process of legally accessing cannabis when you have a chronic health conditionHow medicinal cannabis can assist people who are living with chronic pain Thank you so much for listening to this episode of Let's Talk, Period. with Tegan Scates, founder of High on Hemp. If you loved hearing from Tegan and want more, you can find her on Instagram at @highonhemp. You can also head to their website for blog content, and more info on High on Hemp's agency and creative services, you can do this here. If you want to keep updated with all things Let's Talk, Period. you can follow us on Instagram at @letstalkperiodau.If you want to chat with like-minded people all about the ep today, you NEED to join our Let's Talk, Period. Podcast Community! You can join here.Your host is Isabella Gosling (@i_gosling)
WELCOME TO SPRING and welcome to a brand new episode of LTP! Today's episode is with the delightful Christiane Gurner. Christiane is an academic, published writer, and solo IVF mumma! Christiane has lived with endometriosis and adenomyosis for many years and has undergone nine laparoscopies, before having a hysterectomy recently for her adeno. She has openly shared her experiences of navigating the IVF and assisted fertility world solo, and the emotional toll losing embryos can have with publications such as The Sydney Morning Herald. We chat on; Christiane's endo and adeno story and the subsequent stigma and trauma she's faced through living with invisible illnesses The changes in medical care she received based on changes in her body sizeBarriers Christiane has faced around romantic relationships due to chronic illness The process of embarking on an IVF journey solo, what that was like for her and her advice for others doing the sameChristiane's thoughts on why there is so much shame and stigma associated with fertility procedures even in 2021 The grief and emotions associated with having a hysterectomy In the episode Christiane mentioned a few recommendations she had, you can access them below.Too Peas in a PodcastJacinta Parsons - Unseen Women's Mental Health ClinicThank you so much for listening to this episode of Let's Talk, Period with Christiane Gurner, solo IVF mumma! If you want to keep updated with all things Let's Talk, Period. you can follow us on Instagram at @letstalkperiodau.If you want to chat with like-minded people all about the ep today, you NEED to join our Let's Talk, Period. Podcast Community! You can join here.Your host is Isabella Gosling (@i_gosling)
In 1984, in an unprecedented act of brotherhood, Israel airlifted thousands of persecuted and starving Ethiopian Jews from Africa to Israel. They had been waiting in Ethiopia for millennia, sustained by the hope to return home to the Holy Land. Among the refugees was an 8-year-old boy, Danny Adeno Abebe. Now an Israeli journalist, Abebe tells the story of his family and his village, and the journey they traveled from Ethiopia through Sudan to Israel, and the even longer distance from a rural village life without indoor plumbing, electricity, or books, to a modern society. Many who left the villages did not survive the hardships of the journey, and many of those who did reach the Promised Land were emotionally wounded in the process. Immigrants in all times and places struggle with loss. They struggle to understand and adapt to their new country, to find a way to fit in, and to expand their identity to incorporate the old and the new. But few must leap a cultural gap as wide as that which this group faced. In his new country, Adeno Abebe encountered rejection as well as embrace. He experienced both astonishing support and appalling prejudice. As he matured, he recognized that both attitudes exist among his former countrymen in Africa, as well. From Africa To Zion (Miskal, 2021) is an extraordinary life story, but above all—it is a story about people, about love, and about the importance of family, regardless of skin color or ethnicity. Renee Garfinkel, Ph.D. is a psychologist, writer, Middle East television commentator and host of The New Books Network's Van Leer Jerusalem Series on Ideas. Write her at r.garfinkel@yahoo.com. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/van-leer-institute
In 1984, in an unprecedented act of brotherhood, Israel airlifted thousands of persecuted and starving Ethiopian Jews from Africa to Israel. They had been waiting in Ethiopia for millennia, sustained by the hope to return home to the Holy Land. Among the refugees was an 8-year-old boy, Danny Adeno Abebe. Now an Israeli journalist, Abebe tells the story of his family and his village, and the journey they traveled from Ethiopia through Sudan to Israel, and the even longer distance from a rural village life without indoor plumbing, electricity, or books, to a modern society. Many who left the villages did not survive the hardships of the journey, and many of those who did reach the Promised Land were emotionally wounded in the process. Immigrants in all times and places struggle with loss. They struggle to understand and adapt to their new country, to find a way to fit in, and to expand their identity to incorporate the old and the new. But few must leap a cultural gap as wide as that which this group faced. In his new country, Adeno Abebe encountered rejection as well as embrace. He experienced both astonishing support and appalling prejudice. As he matured, he recognized that both attitudes exist among his former countrymen in Africa, as well. From Africa To Zion (Miskal, 2021) is an extraordinary life story, but above all—it is a story about people, about love, and about the importance of family, regardless of skin color or ethnicity. Renee Garfinkel, Ph.D. is a psychologist, writer, Middle East television commentator and host of The New Books Network's Van Leer Jerusalem Series on Ideas. Write her at r.garfinkel@yahoo.com. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/biography
In 1984, in an unprecedented act of brotherhood, Israel airlifted thousands of persecuted and starving Ethiopian Jews from Africa to Israel. They had been waiting in Ethiopia for millennia, sustained by the hope to return home to the Holy Land. Among the refugees was an 8-year-old boy, Danny Adeno Abebe. Now an Israeli journalist, Abebe tells the story of his family and his village, and the journey they traveled from Ethiopia through Sudan to Israel, and the even longer distance from a rural village life without indoor plumbing, electricity, or books, to a modern society. Many who left the villages did not survive the hardships of the journey, and many of those who did reach the Promised Land were emotionally wounded in the process. Immigrants in all times and places struggle with loss. They struggle to understand and adapt to their new country, to find a way to fit in, and to expand their identity to incorporate the old and the new. But few must leap a cultural gap as wide as that which this group faced. In his new country, Adeno Abebe encountered rejection as well as embrace. He experienced both astonishing support and appalling prejudice. As he matured, he recognized that both attitudes exist among his former countrymen in Africa, as well. From Africa To Zion (Miskal, 2021) is an extraordinary life story, but above all—it is a story about people, about love, and about the importance of family, regardless of skin color or ethnicity. Renee Garfinkel, Ph.D. is a psychologist, writer, Middle East television commentator and host of The New Books Network's Van Leer Jerusalem Series on Ideas. Write her at r.garfinkel@yahoo.com. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network
In 1984, in an unprecedented act of brotherhood, Israel airlifted thousands of persecuted and starving Ethiopian Jews from Africa to Israel. They had been waiting in Ethiopia for millennia, sustained by the hope to return home to the Holy Land. Among the refugees was an 8-year-old boy, Danny Adeno Abebe. Now an Israeli journalist, Abebe tells the story of his family and his village, and the journey they traveled from Ethiopia through Sudan to Israel, and the even longer distance from a rural village life without indoor plumbing, electricity, or books, to a modern society. Many who left the villages did not survive the hardships of the journey, and many of those who did reach the Promised Land were emotionally wounded in the process. Immigrants in all times and places struggle with loss. They struggle to understand and adapt to their new country, to find a way to fit in, and to expand their identity to incorporate the old and the new. But few must leap a cultural gap as wide as that which this group faced. In his new country, Adeno Abebe encountered rejection as well as embrace. He experienced both astonishing support and appalling prejudice. As he matured, he recognized that both attitudes exist among his former countrymen in Africa, as well. From Africa To Zion (Miskal, 2021) is an extraordinary life story, but above all—it is a story about people, about love, and about the importance of family, regardless of skin color or ethnicity. Renee Garfinkel, Ph.D. is a psychologist, writer, Middle East television commentator and host of The New Books Network's Van Leer Jerusalem Series on Ideas. Write her at r.garfinkel@yahoo.com. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/israel-studies
In 1984, in an unprecedented act of brotherhood, Israel airlifted thousands of persecuted and starving Ethiopian Jews from Africa to Israel. They had been waiting in Ethiopia for millennia, sustained by the hope to return home to the Holy Land. Among the refugees was an 8-year-old boy, Danny Adeno Abebe. Now an Israeli journalist, Abebe tells the story of his family and his village, and the journey they traveled from Ethiopia through Sudan to Israel, and the even longer distance from a rural village life without indoor plumbing, electricity, or books, to a modern society. Many who left the villages did not survive the hardships of the journey, and many of those who did reach the Promised Land were emotionally wounded in the process. Immigrants in all times and places struggle with loss. They struggle to understand and adapt to their new country, to find a way to fit in, and to expand their identity to incorporate the old and the new. But few must leap a cultural gap as wide as that which this group faced. In his new country, Adeno Abebe encountered rejection as well as embrace. He experienced both astonishing support and appalling prejudice. As he matured, he recognized that both attitudes exist among his former countrymen in Africa, as well. From Africa To Zion (Miskal, 2021) is an extraordinary life story, but above all—it is a story about people, about love, and about the importance of family, regardless of skin color or ethnicity. Renee Garfinkel, Ph.D. is a psychologist, writer, Middle East television commentator and host of The New Books Network's Van Leer Jerusalem Series on Ideas. Write her at r.garfinkel@yahoo.com. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/african-studies
In 1984, in an unprecedented act of brotherhood, Israel airlifted thousands of persecuted and starving Ethiopian Jews from Africa to Israel. They had been waiting in Ethiopia for millennia, sustained by the hope to return home to the Holy Land. Among the refugees was an 8-year-old boy, Danny Adeno Abebe. Now an Israeli journalist, Abebe tells the story of his family and his village, and the journey they traveled from Ethiopia through Sudan to Israel, and the even longer distance from a rural village life without indoor plumbing, electricity, or books, to a modern society. Many who left the villages did not survive the hardships of the journey, and many of those who did reach the Promised Land were emotionally wounded in the process. Immigrants in all times and places struggle with loss. They struggle to understand and adapt to their new country, to find a way to fit in, and to expand their identity to incorporate the old and the new. But few must leap a cultural gap as wide as that which this group faced. In his new country, Adeno Abebe encountered rejection as well as embrace. He experienced both astonishing support and appalling prejudice. As he matured, he recognized that both attitudes exist among his former countrymen in Africa, as well. From Africa To Zion (Miskal, 2021) is an extraordinary life story, but above all—it is a story about people, about love, and about the importance of family, regardless of skin color or ethnicity. Renee Garfinkel, Ph.D. is a psychologist, writer, Middle East television commentator and host of The New Books Network's Van Leer Jerusalem Series on Ideas. Write her at r.garfinkel@yahoo.com. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/jewish-studies
This episode centers on the critical role that high-performance liquid chromatography (HPLC) plays in the production of adeno-associated viral (AAV) therapies, the latest advances in AAV design and the next steps in their development. Filling me in on all things HPLC and AAVs is Bella Neufeld, Director of R&D at Teknova. Bella reveals the essential validation and quality control steps required for the production of successful and safe AAV therapies and the role that both HPLC and liquid chromatography–mass spectrometry (LCMS) play in these steps. We also explore the latest development targets for these therapies, looking at how AAVs can be targeted to specific sites and tissues before descending into the treacherous topic of reproducibility in the field. Listen today to find out the latest tips for best practice when working with HPLC, LCMS the advantages of LCMS over other analytical techniques to assess empty and full capsids and the key principles of AAV production! ContentsIntro: 00:00-01:25Explaining HPLC and its benefits: 01:25-03:30Developing adeno-associated viruses: 03:30-05:25 Chromatography in validation vs production of AAVs: 05:25-06:15Quality control vs hands on time: 06:15-07:35 Challenges in AAV production: 07:35-08:55Examining the level of empty and full capsids: 08:55-10:00The role of LCMS in determining and validating AAV contents: 10:00-11:30 Tips for best practice when using HPLC: 12:30-13:10The future of HPLC: 13:10-14:20Latest advances in AAV development: 14:20-15:50Targeting AAVs: 15:50-17:20Reproducibility issues in AAV development: 17:20-19:35Outro: 19:35-21:10
This episode centers on the critical role that high-performance liquid chromatography (HPLC) plays in the production of adeno-associated viral (AAV) therapies, the latest advances in AAV design and the next steps in their development.Filling me in on all things HPLC and AAVs is Bella Neufeld, Director of R&D at Teknova. Bella reveals the essential validation and quality control steps required for the production of successful and safe AAV therapies and the role that both HPLC and liquid chromatography–mass spectrometry (LCMS) play in these steps. We also explore the latest development targets for these therapies, looking at how AAVs can be targeted to specific sites and tissues before descending into the treacherous topic of reproducibility in the field.Listen today to find out the latest tips for best practice when working with HPLC, LCMS the advantages of LCMS over other analytical techniques to assess empty and full capsids and the key principles of AAV production!ContentsIntro: 00:00-01:25Explaining HPLC and its benefits: 01:25-03:30Developing adeno-associated viruses: 03:30-05:25 Chromatography in validation vs production of AAVs: 05:25-06:15Quality control vs hands on time: 06:15-07:35 Challenges in AAV production: 07:35-08:55Examining the level of empty and full capsids: 08:55-10:00The role of LCMS in determining and validating AAV contents: 10:00-11:30 Tips for best practice when using HPLC: 12:30-13:10The future of HPLC: 13:10-14:20Latest advances in AAV development: 14:20-15:50Targeting AAVs: 15:50-17:20Reproducibility issues in AAV development: 17:20-19:35Outro: 19:35-21:10 See acast.com/privacy for privacy and opt-out information.
Jay sits down with his long-time friend to discuss Black/Minority professionals in the world of STEM (Science , Technology, Engineering, and Math). Eisha S. Clyde, MS is a scientist at Asklepios Biopharmaceutical, Inc. Her research revolves around T cell & B cell responses to Adeno-associated Virus (AAV) vector. Eisha is a proud HBCU graduate of North Carolina Central University (NCCU), where she received her Bachelor's Degree in Biology in 2015. Her passion for science and interest in scientific research led to her graduate school career -- she attended Towson University. Eisha is the proud Founder and Executive Director of The HBCU STEMuLUS. This nonprofit org is committed to the students of HBCUs (Historically Black College and University). The mission is to ensure that these students are educated, trained, and developed members of the STEM community. Get your pen, paper and search engine ready -- you're about to learn some mind-blowing things!Instagram : Eisha.Clyde / TheHBCUSTEMuLUSFacebook : The HBCU STEMuLUSWebsite : https://thehbcustemulus.org/staging/1282/
Happy Wednesday Let's Talk, Period. fam and welcome back for another ep! Today's episode is with Ashleigh Mason. Ash is a qualified Physiotherapist and Women's Health Educator from Melbourne, with a special interest in trauma informed women's health and chronic pain. In addition to holding a Master's Degree in Physiotherapy, Ash has also completed further studies in the field of women's health including pre and post-natal health, and chronic pelvic pain. She is also passionate about holistic healthcare and is a self love and mindset coach.In this chat we talk on; What led Ash to become a physiotherapist and if women's health physio was always something she envisioned for her careerThe science of pain and how pain works in relation to pelvic pain and chronic painBuckets of care and how they are so important for managing endo or other chronic conditions Factors which can contribute to pain and how to manage these When to refer onto a pelvic physiotherapist and what this might look likeAll about KIC Bump, and working with the Keep it Cleaner team to design a pre and post natal programPlus so much more! If you loved hearing from Ash you can find her on Instagram at @thewomenslifephysio. If you want to keep updated with all things Let's Talk, Period. you can follow us on Instagram at @letstalkperiodau. Also if you haven't already, join the Let's Talk, Period. Podcast Community on facebook! It's a place for like minded individuals to talk on health and wellbeing, as well as all things LTP. You can join here.Your host is Isabella Gosling (@i_gosling)
Hi beautiful souls! Get excited because Let's Talk, Period. is back for Season 3! So welcome back or hello if you're new here! Today's episode is with the incredible co-founder and CEO of the Australasian Birth Trauma Association, Amy Dawes. Amy is an effective advocate for bringing consumers, clinicians and researchers together to support women and families affected by birth-related trauma. In 2017, Amy launched the Australasian Birth Trauma Association (ABTA), she has established a not-for-profit organisation focused on the recognition and understanding of birth-related complications. With a multi-disciplinary advisory group of midwives, physiotherapists, obstetricians, gynaecologists, perinatal psychiatrists and clinical researchers, she is working to develop the resources and strategies to prevent and effectively manage birth-related trauma. Amy's understanding of birth-related trauma has come from her own experience, and the many birthing people she has listened to and helped to find support. Amy's vision is to break down the stigma attached to birth trauma, and empower birthing families to feel comfortable speaking out, so as to continue driving change in current maternity practices in Australia and New Zealand. In this chat we talk on:Amy's experience around birth trauma herself and her postpartum experienceHow Amy dealt with this time and what steps she took after her prolapse diagnosis to feel less alone and more connectedWhy no one is talking about birth injuries and trauma associated with birthingSide effects and feelings around experiencing birth trauma, and how What led Amy to start the Australasian Birth Trauma Foundation [ABTA] and why there was only one other organisation around birth trauma and injury worldwideBarriers and challenges people face when accessing care in the antenatal and postnatal periodAll about Birth Trauma Awareness Week, how you can get involved and support ABTAPlus so much moreThroughout the ep, Amy mentioned lots of amazing resources! You can check them out here:Pelvic Health Physios to Support Birthing Women Petition: http://chng.it/KVfJJFpdABTA Birth-Related Trauma Support Group https://www.facebook.com/groups/birthtrauma.org.auBirth Trauma Awareness Week 2021 - Better Healing: https://www.birthtrauma.org.au/birth-trauma-awareness-week/Register for the WalkNTalk: https://fundraise.birthtrauma.org.au/event/walkntalk/homeIf you loved hearing from Amy, and want more from her you can follow her on Instagram @amydawes07 and Australasian Birth Trauma Association @birthtrauma.org.au. You can also head to their website www.birthtrauma.org.au. If you want to keep updated with all things Let's Talk, Period. you can find us on Instagram at @letstalkperiodau.Thank you so much to Calm Crew for making this episode of Let's Talk, Period. possible! You can find their Calm Crew Fleece bundles right here. Don't forget you can use code 'letstalkperiod25' for a massive 25% off your order. Your host is Isabella Gosling (@i_gosling)
In this episode, I'm speaking to Jodie about endometriosis and what it's been like for her throughout her life. Jodie has spent all her teen and adult life living with and dealing with endometriosis unbeknownst to herself until she was finally diagnosed at 26. In 2019, Jodie set up Endometriosis South Coast, a charity to support and educate others living with endometriosis and adenomyosis and raise awareness of the illness. Everything we discuss in this episode is our own experiences/opinions etc as always, but due to the nature of the topic, I want to reiterate that we are not medically trained so if you are experiencing any symptoms or issues please always consult a medical professional for further help. *** TRIGGER WARNING *** medical surgeries and references/infertility To follow and support Endometriosis South Coast, check them out on the below: Instagram: @endometriosissouthcoast Website: www.endometriosissouthcoast.com FB Support Group: https://www.facebook.com/groups/2736836219689401 As always, please hit subscribe on whatever platform you listen to your podcasts on to make sure you don't miss the next episode, and if you listen on iTunes please leave a review with any thoughts or opinions on this episode or the podcast as a whole, as always, I really love and appreciate hearing from you! Thanks again to Jodie for sharing her experiences and journey so far with Endometriosis, for helping to open up the discussion around Endo and Adeno, and for spreading awareness. Keep up to date with the upcoming episodes, some behind-the-scenes recording pics/vids, and other fun stuff over on Instagram by following @cuppateaandtalkswithg Hope you enjoy this one!!!! Love, G xxx
Den vollständigen Standpunkte-Text (inkl ggf. Quellenhinweisen und Links) findet ihr hier: https://kenfm.de/die-popel-epidemiologie-von-wolfgang-wodarg Ein Standpunkt von Wolfgang Wodarg. Früher betrachtete man sie als gesund und ließ sie in Ruhe: Kinder, die keine Symptome zeigten, deren Nase höchstens ein bisschen lief, gehörten zum Alltag an Schulen. Heute ist jeder ein potenzieller Überträger einer Tod bringenden Krankheit. Man heilt keine Krankheiten, sondern fahndet nach verborgenen Infektionen und treibt so die Fallzahlen nach oben, hält das Land dauerhaft in Angst. Das brüsk in ein kindliches Nasenloch gerammte Wattestäbchen ist zum Symbolgegenstand unserer Zeit geworden. Dr. Wolfgang Wodarg, dessen neues Buch „Falsche Pandemien. Argumente gegen die Herrschaft der Angst“ in diesen Tagen im Rubikon-Verlag erscheint, ist ein erfahrener und unerschrockener Wissenschaftsrebell der ersten Stunde. Viel angefeindet, blieb er seinen einmal für richtig erkannten Thesen treu und spezifiziert sie nun in den Tagen von Massen-Zwangstests und aufdringlichen Impfkampagnen. Er dekonstruiert die irreführenden Zahlenspiele der Angstmacher und zeigt, welche Gefahr von den — speziell für Kinder — völlig unnötigen Impfungen für die Gesundheit ausgehen. Der schwedische Gesundheitsdienst hat am 29. April 2021 nach erneuten ausführlichen Konsultationen mit den zuständigen Fachgesellschaften bestätigt: „Die PCR-Technologie, die in Tests zum Nachweis von Viren verwendet wird, kann nicht zwischen Viren, die in der Lage sind, Zellen zu infizieren, und Viren, die vom Immunsystem inaktiviert wurden, unterscheiden, und daher können diese Tests nicht verwendet werden, um festzustellen, ob jemand infektiös ist oder nicht.“ Die Schweden setzen zur Infektionskontrolle vor allem auf klinische Parameter und entscheiden danach über entsprechende Beratung für Infektiöse und deren Umgebung (1). Tests bei Gesunden oder Symptomlosen gelten in Schweden als unsinnig, so wie bis vor eineinhalb Jahren in Deutschland und anderen Teilen der Welt ja auch. Der deutschen Bevölkerung werden jetzt andere Regeln auferlegt. Sie werden den Menschen nicht von Fachgesellschaften, sondern von der Politik zugemutet. Dabei umgehen Bundesregierung und Länderchefs sogar die Möglichkeit, ihre eigenen hochqualifizierten wissenschaftlichen Nutzenbewerter einzuschalten (2). Erstaunlicherweise hat man bei uns heutzutage etwas eigentlich Selbstverständliches aus den Augen verloren: Wer zum Beispiel als Kind, Jugendlicher oder als Lehrkraft zum Unterricht geht, der ist normalerweise nicht krank. Deshalb werden mit den Testorgien in deutschen Ländern grundsätzlich normal leistungsfähige Lehrkräfte und vor allem Kinder untersucht, denen höchstens mal die Nase läuft. Diese Kinder gehören — besonders im Winter — auch in den Klassenräumen schon immer dazu. Sie durchleben schon immer ohne ernste Probleme die ersten Kontakte mit zahlreichen Atemwegsviren, tauschen diese untereinander aus und werden dadurch für viele Jahre gegen sie immun. Wenn sie nach Hause kommen, lassen sie regelmäßig auch ihre Familie an diesem Immuntraining teilnehmen. Obwohl es sich dabei um Influenza-, Parainfluenza-, Rhino-, Adeno-, RS-, Metapneumo- und eben auch Coronaviren handelt, führt das nur in sehr seltenen Fällen zu stärkeren Symptomen, sondern eher zu Husten, Schnupfen, Heiserkeit. Die allermeisten merken von ihren Viruskontakten jedoch gar nichts. Aus diesen unterschiedlich intensiven, aber regelmäßigen natürlichen Begegnungen resultiert eine zelluläre, langanhaltende Herdenimmunität gegen alles, was so ähnlich aussieht wie die kontaktierten Viren (Kreuzimmunität) (3). In einer Übersichtsarbeit aus dem berühmten La Jolla Institute (4) in San Diego werden 1.434 unterschiedliche Epitope (molekulare Merkmale) bei SARS-CoV-2-Viren aufgeführt, die gegebenenfalls von unseren T-Zellen erkannt werden und eine Abwehrreaktion auslösen. Also auch die immer wieder neuen Mutanten haben keine Chance. Es war und ist unstrittig, dass junge wie ältere Menschen beim Auftreten von Symptomen sich erst einmal auskurieren sollten, bevor sie wieder unter Leute gehen. In früheren Jahren wurde aber kaum einmal ein Kind nur wegen laufender Nase oder etwas Husten nach Hause geschickt. Es waren natürlich schon immer diese kleinen munteren „Superspreader“, welche die Viren allen anderen zugänglich gemacht haben und auch zu Hause bei Eltern und Großeltern für Viren-Updates sorgten. Die derzeitigen popeligen Präventionsmaßnahmen wären vor zwei Jahren wohl noch als Zumutung vom Schulhof gejagt worden. Und das wäre auch weiterhin berechtigt. Nun sind aber die Menschen in vielen Ländern durch Regierungen, Medien und andere Profiteure der Angst — anders als in Schweden — immer noch darauf konditioniert, nicht Kranke, sondern positive Testergebnisse als Zeichen einer Bedrohung wahrzunehmen. Wer die Freiheiten der Menschen durch Bangemachen einschränken möchte, der braucht also gar keine Kranken. Es reicht aus, genügend viele Tests dort zu machen, wo vermutlich viele positive Ergebnisse zu erwarten sind. Derzeit sind die Labore in Deutschland mit wöchentlich über 1 Million PCR-Tests bereits stark belastet. Hinzu kommen die Antigen-Selbsttests. Die Deutsche Gesellschaft für Kinder- und Jugendmedizin e.V. warnte in ihrer Stellungnahme vom 26. März 2021 (5) vor einer wöchentlich zu erwartenden halben Million falsch positiver Tests:…weiterlesen hier: https://kenfm.de/die-popel-epidemiologie-von-wolfgang-wodarg +++ KenFM jetzt auch als kostenlose App für Android- und iOS-Geräte verfügbar! Über unsere Homepage kommt Ihr zu den Stores von Apple und Google. Hier der Link: https://kenfm.de/kenfm-app/ +++ Abonniere jetzt den KenFM-Newsletter: https://kenfm.de/newsletter/ +++ jetzt kannst Du uns auch mit Bitcoins unterstützen. Bitcoin-Account: https://commerce.coinbase.com/checkout/1edba334-ba63-4a88-bfc3-d6a3071efcc8 +++ Dir gefällt unser Programm? Informationen zu weiteren Unterstützungsmöglichkeiten findest Du hier: https://kenfm.de/support/kenfm-unterstuetzen/ Website und Social Media: https://www.kenfm.de https://www.twitter.com/TeamKenFM https://www.instagram.com/kenfm.de/ https://soundcloud.com/ken-fm https://t.me/s/KenFM See acast.com/privacy for privacy and opt-out information.
Historically, Adenomyosis was a pathological diagnosis only. However, new imaging standards/techniques have moved Adeno into a clinical diagnosis. Is there a patient risk profile for this condition? Is this strictly a gynecological issue or is there adverse perinatal outcomes as well? Welcome to Part 1 of Adenomyosis where we will answer these questions and more.
„Johnson & Johnson“ gamintojo vakcina Janssen Europoje buvo patvirtinta dar kovą. Balandžio viduryje sulaukėme ir pirmosios šių vakcinų siuntos, tačiau krovinio iki šiol taip ir nepradėjome naudoti. Mat kilo tokių pat neaiškumų, kaip ir su „AstraZeneca“ kompanijos gaminiu – įtariama, kad ir ši vakcina gali didinti krešulių susidarymo riziką. Kol Europos vaistų agentūra atlieka atvejų, susijusius su Janssen vakcina, tyrimą, apie 5 tūkst. gautų jų dozių saugiai guli Lietuvos sandėliuose. Sutapimas ar ne, kad kraujo krešulių susidarymo rizika siejama būtent su tomis vakcinomis, kurių pagrindą sudaro negyvas Adeno virusas, į kurį įterptas koronaviruso spyglio baltymą veikiantis genas?Kitas visuomenę neraminantis klausimas – vaikų saugumas COVID-19 akivaizdoje. Sveikatos apsaugos ministerija tikina, kad 70 proc. Lietuvos visuomenės bus paskiepyta iki liepos 6 dienos. Tačiau į šį skaičių neįtraukiami vaikai, mat Lietuvoje yra tik viena vakcina, kuria galima skiepyti paauglius nuo 16 metų. O ką daryti su jaunesniais gyventojais? Ar saugu planuoti vasaros atostogas užsienyje, jei abu tėvai nuo COVID-19 paskiepyti, o atžala – ne?Neramu ir onkologinėmis ligomis sergantiems pacientams, kurie dviem vakcinos dozėmis jau yra paskiepyti, o antikūnų testas praėjus mėnesiui po paskutinio dūrio – neigiamas. Ar gali vakcinos efektyvumui įtakos turėti taikomas aktyvus gydymas?Laidoje dalyvauja Valstybinės vaistų kontrolės tarnybos Farmakologinio budrumo ir apsinuodijimų informacijos skyriaus vyresnioji patarėja Rugilė Pilvinienė, Vilniaus Universiteto Medicinos fakulteto profesorius Vytautas Usonis ir Nacionalinio vėžio instituto gydytoja onkologė-chemoterapeutė dr. Edita Baltruškevičienė.Ved. Laura Adomavičienė
Happy Wednesday lovelies! What better way to kick off Adenomyosis Awareness Month than with the incredibly strong Jess Woolley, founder of @jesshasadeno and adenomyosis advocate. Jess started her instagram account in 2018 after finally being diagnosed with adenomyosis, after years of wondering what was wrong with her body. She has cultivated a following for speaking openly about her experiences with not only adenomyosis, but also mental health. Jess wants the lack of awareness for adeno to end, and for more people to be speaking openly about the condition.In this chat we talk on:What it feels like to finally receive that diagnosis after years of being told nothing's wrong for yearsProcessing anger around having adeno, as well as her tips for working through thisWhy Jess started @jesshasadeno and the community she has cultivated as a resultJess' experience with mental health, starting medication and ending medication stigmaStudying when you have a chronic illness and her top tips for doing soHow Jess manages guilt around her adenomyosisWhat adeno has given herPlus so much moreIf you loved our chat with Jess, and want more from her you can find her on Instagram @jesshasadeno. If you want to keep updated with what we're up to you can follow us on Instagram at @letstalkperiodau. If you do enjoy listening and want to be notified when our new eps drop, you can subscribe or follow the show! We would also love it if you shared this episode with a friend or family member, or even show us how you're listening! Tag us on instagram stories or in your grid, it really does help us out and helps us grow our community!Your host for this episode is Isabella Gosling (@i_gosling)
Adeno hipófise
Helloooooo! It's Wednesday and it means we're back with Episode 4 for Season 2 of the pod! Today's chat is with the super knowledgeable Christie Lee Austin-Hore! Christie is an Accredited Practising Dietitian based in Perth, WA who specialises in endometriosis. Christie is passionate about helping all endo warriors reduce the amount of surgery and medication they require to manage flare-ups of endo pain, bloating, alternating bowel habits and fatigue as well as future-proofing their fertility. After hitting maximum client capacity in her online consulting business after only five months of operating, she has recently turned her unique framework for managing combined endometriosis and IBS, more commonly known as endo belly, into an online six month program called Beat the Endo Belly. In this chat we talk on:The connection between endo, bloating and IBSCaffeine and the effects on endoWhether going gluten and dairy free are best for managing endoFatigue and endoPlus so much more!If you loved our chat with Christie, and want more from her you can find her on Instagram @endometriosis.dietitian or via her website here. If you want to keep up with what we're up to you can follow us on Instagram at @letstalkperiodau. If you do enjoy listening and want to be notified when our new eps drop, you can subscribe or follow the show! We would also love it if you shared this episode with a friend or family member, or even show us how you're listening, tag us on instagram stories or in your grid, it really does help us out and helps us grow our community!Your host for this episode is Isabella Gosling (@i_gosling)
Happy Wednesday! We're back for Episode 3 of Season 2, and it's with none other than Founder and Managing Director of Share the Dignity, Rochelle Courtenay! Nicknamed ‘The Pad Lady', Rochelle is a woman on a mission to end period poverty, and break the silence and stigma that surrounds women and periods in Australia and globally. She's the Founder and Managing Director of Share the Dignity, a charity she started single-handedly in 2015 when she discovered that women in need in Australia had no access to period products during their menstrual cycle. Share the Dignity started from a simple, grassroots idea of wanting to improve the lives of disadvantaged women, and Rochelle forged ahead on the belief that one person could indeed make a difference. Along the way, her dedication inspired others to join in. Today, she leads a team of over 5500 volunteers determined to bring a ray of hope and light into the lives of homeless women and those fleeing from abuse and domestic violence. Share the Dignity has donated over 2.8 million period products (over 37 million dollars' worth) through multiple initiatives across Australia. Rochelle has also won recognition and accolades for her work including Finalist Australian of the Year, Cosmopolitan Humanitarian of the Year and Pride of Australia.In this chat we talk on:When Rochelle realised having painful and heavy periods wasn't normal, and that she actually had endometriosisWhat prompted Rochelle to start Share The DignityThe first Dignity Drive, where she organised with women in her community to donate 450 packets of pads and tampons to women in needHow Rochelle evolved and grew Share The Dignity to have now collected over 2.8million period products and collection boxes in every Woolworths across AustraliaThe highlights of Share The Dignity so farAll about Period Pride and the Bloody Big Survey and how you can get involvedWhat's coming up next for Share The DignityHow you can support Share The DignityPlus so much moreIf you loved our chat with Rochelle, and want more from her you can find her on Instagram @sharethedignityaustralia or via the The Share the Dignity website here. If you want to keep up with what we're up to you can follow us on Instagram at @letstalkperiodau. If you do enjoy listening and want to be notified when our new eps drop, you can subscribe or follow the show! We would also love it if you shared this episode with a friend or family member, or even show us how you're listening, tag us on instagram stories or in your grid, it really does help us out!as this helps us grow our community!Your host for this episode is Isabella Gosling (@i_gosling)
This week's episode features author Torbjørn Omland and Senior Guest Editor Vera Bittner as they discuss the artile "Growth Differentiation Factor-15 Provides Prognostic Information Superior to Established Cardiovascular and Inflammatory Biomarkers in Unselected Patients Hospitalized with COVID-19." TRANSCRIPT BELOW: Dr. Carolyn Lam: Welcome to Circulation on the Run, your weekly podcast summary, and backstage pass to the journal and its editors. We are your co-hosts, I'm Dr. Carolyn Lam, associate editor from the National Heart Center and Duke National University of Singapore. Dr. Greg Hundley: I'm Dr. Greg Hundley, Director of the Pauley Heart Center at VCU Health in Richmond, Virginia. Well, Carolyn our feature this week gets into inflammatory biomarkers in patients that have been hospitalized with COVID-19, but before we get to that, how about we grab a cup of coffee and work through some of the papers in the issue. Would you like to go first? Dr. Carolyn Lam: Absolutely. With both the coffee and the papers. So great, for this first paper, have you thought about concentric versus eccentric cardiac hypertrophy? We traditionally associate them with pressure versus volume overload respectively in cardiovascular disease, both though conferring an increased risk of heart failure. These contrasting forms of hypertrophy are characterized by asymmetric growth of the cardiac myocytes in mainly width or length respectively. However, the molecular mechanisms determining myocyte preferential growth in width versus length remain poorly understood. Dr. Carolyn Lam: That is until today's paper, and it is from Dr. Kapiloff from Stanford University, and Dr. Rosenfeld from UCSD, School of Medicine and their colleagues, and what they did was used primary adult rat ventricular myocytes, as well as Adeno associated virus mediated gene delivery in mice, to define a regulatory pathway controlling pathological myocyte hypertrophy, and they found that asymmetric cardiac myocyte hypertrophy is modulated by serum response factor phosphorylation, constituting an epigenomic switch balancing the growth in width versus length of adult ventricular myocytes In vitro, and In vivo. Dr. Carolyn Lam: Serum response factor phosphorylation was bi-directionally regulated at signalosomes organized by the scaffold protein muscle, A kinase anchoring protein beta. This newly identified molecular switch controlled a transcriptional program responsible for modulating changes in cardiomyocyte morphology that occurs secondary to pathological stressors. Dr. Greg Hundley: Very nice, Carolyn. So switches controlling this transcriptional program. Tell us a little bit, and bring us back to the clinical relevance of this and starting with that concentric versus eccentric hypertrophy? Dr. Carolyn Lam: I thought you may ask. The identification of a molecular mechanism regulating that asymmetric cardiomyocyte growth, really provides a new target for the inhibition of pathological cardiac hypertrophy. Studies in mice using these Adeno associated virus based gene therapies to modulate that signalosome, really provided proof of concept for translational potential in the treatment of pathological cardiac remodeling and prevention of heart failure. Dr. Greg Hundley: Oh, wow. Very nice, Carolyn. Well, my first paper comes to us from Professor Dirk Westermann from Hamburg, and focuses on cardiogenic shock patients, and veno-arterial ECMO, the results from the international multicenter cohort study. So Carolyn this study evaluated data from 686 consecutive patients with cardiogenic shock treated with VA ECMO with or without left ventricular unloading using an Impella, and they conducted this at 16 tertiary care centers across four countries. They examined the association between left ventricular unloading and 30 day mortality. Dr. Carolyn Lam: Huh, so what did they find? Dr. Greg Hundley: Okay. Carolyn. Well, left ventricular unloading was used in 337 of the 686 patients enrolled, and after propensity matching 255 patients with left ventricular unloading were compared with the 255 patients without left ventricular unloading. In the match cohort, left ventricular unloading was associated with lower 30 day mortality without differences in the various subgroups. However, complications occurred more frequently in patients with left ventricular unloading, like severe bleeding, which happened in 38.4% versus only 17.9% in those without unloading. There was also access-related ischemia and renal replacement therapy. Dr. Greg Hundley: So Carolyn, the take-home message from this International multi-center cohort study, is that left ventricular unloading is associated with lower mortality, and cardiogenic shock patients treated with VA ECMO, despite higher complication rates. In the absence of randomized trial data these findings support the use of left ventricular unloading and cardiogenic shock patients treated with VA ECMO, and call for further validation, ideally in a randomized controlled trial. Dr. Carolyn Lam: Very nice. Well for my next paper, Greg, it's all about desmin. Now we know that mutations in the human desmin gene caused myopathies and cardiomyopathies. Well, today's authors, Dr. Hermann and Schroeder from University Hospital Erlangen in Germany and Dr. Lilienbaum from University of Paris and France and their colleagues, report an adolescent patient who underwent cardiac transplantation, due to restrictive cardiomyopathy caused by a heterozygous R406W desmin mutation. Sections of the explanted heart were analyzed with antibodies specific to 406W-desmin, and to intercalated disc proteins. Effects of this mutation on the molecular properties of desmin were then addressed by cell transfection and In vitro assembly experiments. They further generated these desmin mutation knock-in mice haboring the orthologous form of the human, R406W-desmin. Dr. Greg Hundley: So Carolyn, what did they find? Dr. Carolyn Lam: Well, they demonstrated a novel pathomechanism in which cardiotoxic R406W-desmin, could adapt dual functional status with the abilities to integrate into the indogenous intermediate filament network, and to cause formation a protein aggregates. This R406W-desmin modified the extra sarcomeric cytoskeleton, such that desmin filaments were not anchored to desmosomes anymore. Thereby destroying the structural, and functional integrity of intercalated discs. Dr. Greg Hundley: What are the clinical implications? Dr. Carolyn Lam: Well, since these cardiotoxic desmin mutations could affect the integrity of intercalated discs, thereby inducing conduction defects and malignant arrhythmias, they suggest early implantation of pacemaker, or cardioverter defibrillator devices, may be considered to prevent certain cardiac death in patients with these mutations. Furthermore, state-of-the-art basic molecular risk stratification of desmin mutations may encompass a multidisciplinary experimental approach as exemplified by the approach taken here, which comprises assessment of the tissue pathology in conjunction with genome analysis and desmin assembly studies as well as patient mimicking cell and animal models for the In vivo validation of these mutations. Dr. Greg Hundley: Well, fantastic, Carolyn. Well, my next paper comes to us from Dr. Ravi Shah from the Massachusetts General Hospital. This study evaluated 2,330 white and black young adults, average age of 32 years, in the Coronary Artery Risk Development in Young Adults, or the cardiac study, to identify metabolite profiles associated with an adverse cardiovascular disease phenom that included, myocardial structure and function, fitness, vascular calcification, and then also mechanisms, and other cardiovascular outcomes that would occur over the next two decades. Statistical learning methods, including elastic nets and principal component analysis, and Cox regression generated parsimonious metabolite based risk scores, validated in over 1800 individuals in the Framingham Heart Study. Dr. Carolyn Lam: Wow. What did they show, Greg? Wow, that's a lot of work. Dr. Greg Hundley: Yeah. So Carolyn, the authors found two multiparametric metabolite-based scores linked independently to vascular, and myocardial health. With metabolites included in each score specifying microbial metabolism, hepatic steatosis, oxidative stress, nitric oxide modulation, and finally collagen metabolism. Over nearly 25 year median follow-up, and cardia, this metabolite based vascular score, and the myocardial score, and the third and fourth decade of life were associated with clinical cardiovascular disease. Importantly, the authors replicated these findings in 1,898 individuals in the Framingham Heart Study followed over two decades, such that young adults with poor metabolite based health scores had higher hazard ratios of future cardiovascular disease related events. Dr. Carolyn Lam: Oh wow. Greg, what an elegant study with both development and validation cohort evaluating the metabolome. Dr. Greg Hundley: Yes. Carolyn. So metabolic signatures of myocardial, and vascular health in young adulthood specify known novel pathways of metabolic dysfunction, relevant to cardiovascular disease associated with outcomes in two independent cohorts. So these data suggests that efforts to include precision measures of metabolic health in risk stratification to interrupt cardiovascular disease at an early at stage, are warranted. Dr. Carolyn Lam: Wow. So interesting. Other very interesting articles in today's issue, there's an In Depth article by Dr. Angiolillo entitled, “The Antithrombotic Therapy for Atherosclerotic Cardiovascular Disease Risk Mitigation in Patients with Coronary Artery Disease and Diabetes.” There's also Research Letters, one by Dr. Sultan on, “The Longterm Outcomes of Primary Cardiac Lymphoma” and one by Dr. Wang on, “Loss of Phosphatase and Tensin Homolog Promotes Cardiomyocyte Proliferation and Cardiac Repair Following Myocardial Infarction.” Dr. Greg Hundley: Great, Carolyn. Well, I've got a couple other articles in this issue as well. One is by Professor Ganesan Karthikeyan who has an On My Mind piece entitled an “Alternative Hypothesis to explain Disease Progression in Rheumatic Heart Disease.” Dr. Stuart Chen has an ECG challenge entitled, “Alternating QRS Duration and a Normal T-waves. What is the mechanism?” Then finally, Carolyn, a series of Letters to the Editor, one by Dr. Peterzan and the other by Dr. Mehmood regarding the prior published article, entitled “Cardiac Energetics in Patients with Aortic Stenosis and Preserved Ejection Fraction.” Well, Carolyn, how about we get onto that feature article and learn more about inflammatory biomarkers in hospitalized patients with COVID-19? Dr. Carolyn Lam: Yes. Let's go. Greg. Biomarkers are really playing an increasingly important role in cardiovascular disease, and even in the current COVID 19 pandemic, there's been a lot of news about how biomarkers such as traponin may be prognostic, and in fact, we're all wondering about maybe even newer biomarkers. In fact, today's feature discussion does bring to light one of the newest, and in fact, this is the first publication on the role of Growth Differentiation Factor 15 or GDF-15 in COVID-19. We're so pleased to be discussing this with the corresponding author, Dr. Torbjørn Omland from University of Oslo, in Norway, as well as our senior guest editor, Dr. Vera Bittner from University of Alabama at Birmingham. So welcome both. Tobjorn, could you tell us a little bit about GDF-15 and what made you look at it, and what did you find? Dr. Torbjørn Omland: Yeah, so GDF-15, that's a very interesting biomarker. It's considered a biomarker of biological aging cellular stress, and perhaps also the inflammation, and tests being studied within the cardiovascular field for some years now, and it has been shown to be a strong prognostic indicator across the cardiovascular spectrum, actually. So it is a new biomarker in one sense, but there are some data already in the cardiovascular field. Dr. Carolyn Lam: Not in COVID. So this is the first study to really look at its prognostic value in COVID 19. So congratulations Torbjorn, and if I may also to the first author, Dr. Peter Meer, a good friend as well, but please, could you tell us about your study and what you found? Dr. Torbjørn Omland: Yes. So when the COVID pandemic hit Norway in the spring, we thought that we should plan a prospective biomarker study. So we had to really fast track approval by the IRB and so forth, and we're able to actually cover most of the patients that were hospitalized in our hospital, Akershus University hospital, which is right outside of Oslo, and it's a pretty large hospital by Norwegian standards. It covers about 11% of the Norwegian population. Dr. Torbjørn Omland: So in that period, when we were including, we had 136 patients hospitalized with confirmed COVID 19, and we have biobank bank samples from 123 of these, and then there have been reports from retrospective studies, first from China, that seemed to suggest that markers like cardiac troponin, Anti-Troponin T, and Ferritin were associated with outcome, but those studies were prone to selection bias in that the measurements were performed in the most sick patients. So in this study we included all patients and then we thought we should examine a broad panel of biomarkers, and that included Interleukin 6, CRP, Procalcitonin, Ferritin, and the D-dimer Cardiac troponin, and N-terminal pro B, and GDF-15. Dr. Carolyn Lam: Wow. Thank you, Torbjorn. Even before you carry on with the results, can I just say having visited your hospital in pre-COVID days, I can only imagine what a work of love this was to do it prospectively. Any particular experiences to talk about, to get a fast-track even in the midst of to perform a well done prospective study, that must have taken a lot. Dr. Torbjørn Omland: Yes. But it's also interesting in that the whole sort of ablation on Norway was very much into this from the highest political level. Also, the decision that the older research on COVID should be prepared to retire, then the IRB had an eight hour and deadline for them to approve or not approve the study. So that's went surprisingly smoothly, I must say. Dr. Carolyn Lam: Wow, that's great. So what did you find? Dr. Torbjørn Omland: Yeah, so we found that among these biomarkers, several seem to predict outcome, and the primary end point of this study was to combined end-point of the hospitalization in the ICU, or death. We found that also markers like cardio traponin, BNP, ferritin, and the D-dimer and so forth, in univariable analysis, were very associated with outcome, but when we perform a more comprehensive, mostly variable modeling, then the prognostic value of some of these markers disappeared. In contrast, for GDF-15, it seemed to perform very strongly, both on the baseline sample, and interestingly also it increased in those reaching the primary end-point during the hospitalization. So it provided a very strong and independent information also when we adjusted for clinical risk scores, like the NEWS score. So that was a very pleasant surprise to see that there was one marker that's actually performed so well. The other marker that's also performed well was Ferritin. Dr. Carolyn Lam: Very interesting, and so the new score being the National Early Warning Score. Thank you. Verra, I really love to bring in your thoughts. I mean, could you take us behind the scenes with the editors? What did you think when you saw this paper? Dr. Vera Bittner: As you know, I mean, a lot of journals have been inundated by COVID papers, and so this one stuck out to us, because it's the first time that we had seen that anybody linked GDF-15 to a COVID population, even though it has been out in the literature for ACS, and in my prognostication, and in a healthy populations, and in chronic coronary disease populations, heart failure, and so on. So this is the first time that we've seen it applied there. Dr. Vera Bittner: Then I would echo some of the things that Torbjorn said, that we were also impressed, that it was prospective, because when you look at some of the other biomarker studies, what was prognostic in one with then not shake out the other one, because either different variables were included in the models, because the population's differed. So to have something that was representative of the population that was actually admitted to this, Norwegian Academic Hospital, stood out to us. So we're excited to get this paper basically for circulation, and hope that it also will be impetus for future research. Dr. Carolyn Lam: Thank you so much for sharing that end for helping us publish such a beautiful paper. Did you have some questions for two of your own? Dr. Vera Bittner: Yeah. So what stuck out to me is that you had this a whole crew of biomarkers, and then when you looked ultimately at the final model, there were two that were standing out, that was ferritin, and it was the GDF-15, and then when I looked at your graph, it looks like not only did these biomarkers measure different contrasts, but their time-course also seemed to be different, and so I was just wondering whether you had thought about, maybe using these to joint the model outcome, and whether we might even be able to get more information that way. Dr. Torbjørn Omland: I think that's an excellent suggestion, and as you correctly pointed out, they do have different sort of profiles and ferritin being an acute phase reactant, having various sort of dramatic early rise whereas we see that GDF-15 increased progressively during the course of hospitalization in the most severe patients. I think when combining them, is actually a great IMT that we should look further into. Dr. Carolyn Lam: Very nice. Torbjorn, if I could, I've got a couple of questions too. So 123 patients, 35 of whom had the primary outcome, right? So that may be sort of seen as, is this too small? and they're all hospitalized patients. So could I ask, what do you predict maybe seen in a larger population or outside of Norway or in a non-hospitalized population? Dr. Torbjørn Omland: So as you say, we were early with this report, but since it was submitted, there has been a couple of smaller studies that seemed to confirm our results. So that is reassuring, but of course we would like to have studied this in logical patients. We are in touch with the other biobank samples that could possibly confirm the data. So that's one obvious step. Then it's very interesting, as you say, could we sort of expand this to also apply to non-hospitalized patients? I think that it would be a very interesting hypothesis to test, and I think there's still a pretty good rationale for this. Dr. Torbjørn Omland: It's interesting that the insoluble group actually showed a correlation that when the soluble ST2 concentrations and GDF-15. So there might be that those with more susceptibility to COVID infections, actually, I thought that, that is actually reflected by GDF-15 concentrations, but the challenge is how to sort of get a representative non-hospitalized population, but interestingly, I was approached by some of the hospital staff that actually are in contact with general practitioners, and wanted sort of implement this test also for this group. Dr. Carolyn Lam: So Verra, we're really grateful that Allan Jaffe was working with you in managing this beautiful paper, and if you don't mind me cheekily paraphrasing that you said you might channel him, if you could, what would the channeled Allan Jaffe perhaps say about what's needed in this whole biomarkers fear in COVID-19? Dr. Vera Bittner: Hopefully, many. A channeling element is obviously difficult, because he is such an incredible expert on biomarkers that I can't even pretend to be able to see, that you might be thinking, but it seems to me that one thing that we could all agree on is that it would be really exciting if something like the: get with the guidelines COVID registry, could decide to measure this marker perspectively in the participating hospitals, for example. Dr. Vera Bittner: Then be able to look at this in a much, much larger population. I mean, especially with different ethnic backgrounds as well. I mean, I noticed actually to my surprise that, this Norwegian study how to fairly high proportion of Asians in the sample, but that may not be the ethnic distribution that we might see in different regions of the US, or different regions of the world. So it would be really nice to incorporate the measurement of this biomarker in much larger datasets. So things can be explored a bit further. Dr. Carolyn Lam: That's excellent, and Torbjorn, if you could channel Allan. What would you say? Dr. Torbjørn Omland: That's a difficult path, but absolutely just to me what Verra said. Then I think the importance of prospective studies in the COVID biomarker field, I think is our at most importance. Dr. Carolyn Lam: I think on behalf of both Torbjorn and I, and in fact everyone in circulation. Thank you, Verra for the amazing work that you and your team do for circulation as well. Thank you so much for making the time to share your thoughts today and thank you for that beautiful, beautiful paper both of you. Thank you. (singing). Listeners you've been listening to Circulation on the Run. Thank you for joining us from Greg and I. Don't forget to tune in again next week. Dr. Greg Hundley: This program is copyright, the American Heart Association 2020.
pomeさんをゲストに迎え、ボストン界隈を中心としたCRISPR関連のバイオスタートアップについて話を伺いました。Show notes Top CRISPR Startup Companies Changing the Future of Biotech and Medicine … CRISPR関連スタートアップまとめ Researchat.fm, ep76 … ゲノム編集特集回 Researchat.fm, ep77 … ゲノム編集特集回 Researchat.fm, ep2 … CRISPR特集回 Researchat.fm, ep77 Researchat.fm, ep47 … SHERLOCKについて話しました。 Boston MIT … マサチューセッツ工科大学。Kendall Station近くに位置する。厳密にはボストン市ではなく、ケンブリッジ市である。 Harvard University … ハーバード大学。こちらもメインキャンパスはケンブリッジ市。Oxford Stに位置する建物もあるため、Oxford St., Cambridgeと住所的には何が何だかわからないところもある。 Boston University … BU University of Massachusetts … UMass Tufts University Berklee College of Music … いつもバークリーなのかバークレーなのかわからなくなる。有名な音楽学校。 NOVARTIS Takeda Biogen Bayer Cell Press … いわゆるCell誌。MIT,ハーバードの目と鼻の先にある。 カリフォルニア州 マサチューセッツ州 ニューヨーク州 ニュージャージー州 Akamai Feng Zhang David Liu Researchat.fm, Ep60 … 培養肉などについて話しました。 GMO …Genetically modified organism Plantedit FAD2 Solive … by Plantedit spCas9 Cas12 Cas13 Inscripta mad7 nuclease Unreal Engine Unity C4U BioPallete Cas3 モダリス Beam Therapeutics Researchat.fm, ep22 … Base editorやTarget AIDについて話しました。 in vivo ex vivo 鎌状赤血球 CRISPR Therapeutics 造血幹細胞 CD34+ ヘモグロビン BCL11A eGenesis Bio George Church 胚盤胞置換法 Living cell technologies (LCT) Diatranz Otsuka CAR-T レンチウイルス AAV HIV ゾルゲンスマ TLO … Technology License Organizationの略 Wyss Institute Wyss Instituteのポッドキャスト … めちゃくちゃ良い。tadasuはリピートしまくって聞いている時期が度々ある。 Peng Yin Researchat.fm, ep74 … DNA Origamiについて話しました。 Cambridge Innovation Center (CiC) Venture Cafe Venture Cafe Tokyo … 虎ノ門ヒルズ内にある。木曜日にイベントをやっているようです。 CiC Tokyo … 虎ノ門ヒルズ内にある。 Cambridge City, MA … ケンブリッジ市 スタンフォード大学のパテントに関する資料 … Stanford UniversityのOTLによる資料。 lab central Johnson & Johnson Roche Job Description 四行教授 … とあるブログ様を引用させていただきました。当時修士のtadasuに四行教授や「履歴書を汚せ」と説いた人物は黒川清先生です。 Researchat.fm, ep75 … I’m not sure though. Editorial notes とっても楽しいおしゃべりでした。仕事と関係ないマニアックな話をできる場はあんまりないので貴重です。またやりましょう。(pome) 後編もお楽しみに〜 (soh) 同じ地区に住んでいるのに何にも活かせていません…(tadasu) (coela)
Mara is 36 years old from WI. She had heavy and long periods starting at 15 years old, at 17 years old she had her first GYN appointment where she was put on Birth Control which helped reduce her cramps, but as years went on in her twenties she began to have increased symptoms such as large blot clots, back pain, pain that felt like contractions and GI symptoms. At 26 she was googling and self-diagnosed with endo... about 6 weeks out from her wedding, 3 weeks before she got married she had surgery! She had back surgery and post-surgery she had bladder retention one month after surgery due to the inflammation of her uterus. Over the next 10 years, she had surgery, changed her diet, and was diagnosed with Adeno. Listen to the rest of her journey on the show. Want to keep the conversation going? Join our Facebook Group: tiny.cc/7mpbnz Thank you for listening and supporting this podcast. We need awareness about this disease. If you want to be on the podcast or have feedback please reach out via my website www.melissaboudreau.com. Thank you for your support and time. Please consider subscribing and writing us a review on Apple podcasts it really helps us get more awareness and with guests agreeing to come on! You can do that here! http://tiny.cc/f74onzSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Powered by synthetic biology, Pierce Ogden makes ALL possible mutations to an adeno-associated virus (AAV) outer shell and rapidly screens them to dissect their attributes. Pierce discusses the technological advances that make this breakthrough screen possible and the novel properties that were discovered. AAVs are rapidly becoming the prefered way to perform gene therapy, correcting cells that carry disease-causing mutations through genetic modification. This technology forms the basis for company Dyno Therapeutics.About the AuthorPierce performed this work as a postdoc at Harvard University in the lab of Professor George Church. Professor Church is one of the founding fathers of synthetic biology and the lab is renowned for developing high throughput methods to design, build, and test bioengineered parts.In his role as Co-Founder & CSO at Manifold Bio, Pierce utilizes his multiplexing expertise to uncover the design principles of protein therapeutics and make new drugs faster than ever before.Key TakeawaysGene therapy uses genetic information as a drug, correcting cells that carry disease-causing mutations.The inability to deliver these genes to the correct cells limits the widespread adoption of gene therapy.Adeno-associated viruses (AAVs) are an extremely promising way to deliver DNA to human cells. Their outer shell, or capsid, can be engineered for increased safety, specificity, and shelf-life.Using advances in DNA synthesis technology, all possible single mutations to the AAV capsid are generated.With a DNA barcode read through next generation sequencing, this AAV library was simultaneously tested cheaply and quickly to find mutations with improved properties.Increased thermal stability, evasion of immune responses, and specificity toward the brain were all found. TranslationPierce demonstrates that smart usage of our synthetic biology toolbox can allow millions of protein variants to be tested simultaneously, in direct opposition to the “tested in parallel” model that has dominated high-throughput biology.Manifold Bio takes this idea of DNA barcodes coupled with simultaneous screening and points it toward the field of protein therapeutics.First Author: Pierce OgdenPaper: Comprehensive AAV capsid fitness landscape reveals a viral gene and enables machine-guided design. Science, 2020.Follow Fifty Years on Twitter!If you’re an author of an upcoming paper in bio or know of any interesting papers dropping soon and want to hear from the authors, drop us an email at translation [AT] fifty [DOT] vc.
This week’s episode is all about Adenomyosis (Adeno), often called the sister to Endometriosis. I had a great interview with Sara Lopez, who has Adeno, and who is also an Adenomyosis Coach. According to one study, that Sara mentions in the interview, 91% of women with Endometriosis have Adenomyosis, they just may never know. In this episode we talk about the symptoms, differences from Endo, how to get it diagnosed, how you can manage it with a holistic approach, how it might fertility and more. Sara Lopez, M. Ed. is a Certified Hormone Specialist and Adenomyosis Coach. She works with women who struggle with adenomyosis or heavy periods to find healing and relief holistically. Sara has always cared about women’s health, and when she was a teen her mother suddenly had a hysterectomy - her recovery was long and painful to watch. She decided she wanted to help others find alternative ways to heal besides hysterectomy. She wanted to be that woman that says “of course you can find relief holistically”, so she became a women’s health coach. Now that I’ve seen so many women have huge health shifts with a holistic approach, I can say that it IS possible if you are ready! The things we discussed were: Sara’s journey with Adenomyosis What Adenomyosis is and the comparison to Endometriosis Symptoms of Adenomyosis Methods of diagnosis How to address low iron resulting from heavy periods How Adeno affects fertility Sara’s holistic approach to reducing her and her client’s symptoms including lymphatic drainage, castor oil packs, acupuncture, abdominal massage, nutrition, gut healing. How lymph affects nerves around the abdomen Localised estrogen in the uterus and progesterone-receptor issues Mast cells, histamines and estrogen Gush Beauties – Sara’s online magazine for women with Adenomyosis Mentioned resources: Download Sara’s Course: The Heavy Period Reset - Using Your Intuition to Find Relief: https://saralopezllc.vipmembervault.com Thorne Research Ferrasorb Berberine (form of Goldenseal) Connect with Sara Lopez at: Website: gushbeauties.com Social Media: @saralopezhealth Email: sara@gushbeauties.com Further EndoFertility links and resources: Join my Endo Fertility community! Find us in the Thrive and Conceive with Endometriosis Facebook Group. The Endo Fertility Specialist website: https://www.endofertilityspecialist.com Follow me on Instagram (@endofertilityspecialist) and Facebook (@endofertilityspecialist) Intro/Outro Music Credits: Optimistic Future This episode is sponsored by the Endo Fertility Resource Library where you can get your 3 amazing freebies: E-Book: 5 Things I Learnt to Drop My Pain & Optimise My Fertility, Your Guide to Super Sperm, and 88 Ways I Dropped My Pain and Got Pregnant. Make sure you hit SUBSCRIBE so you don’t miss out on any future episodes – which will be out weekly on Wednesdays! And, if you enjoyed this episode, please leave me a rating and a review, it will help it reach many more that need help on their Endometriosis and fertility journeys. Thank you! If you want to be on the podcast or have feedback please email: info@endofertilityspecialist.com This podcast is for educational purposes only. The host claims no responsibility to any person or entity for any liability, loss or damage caused or alleged to be caused directly or indirectly as a result of the use, application, or interpretation of the information presented herein.
This lovely afro-Latina is fighting for #Adenomyosis awareness and research. Shamitris dealt with countless doctor visits, many of them disregarding her telling her it is all in her head! We all know when we feel pain, we're not making it up -- it is real. She finds relief now with CBD, holistic treatments like Acupuncture and more. She also writes about her journey to raise awareness and understanding towards Adenomyosis to ultimately help other Adeno-warriors out there. Check out her website: https://www.mypeachfuzz.com and connect with her on Instagram: @mypeachfuzzblog
Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.10.09.332619v1?rss=1 Authors: Woerner, T. P., Bennett, A., Habka, S., Snijder, J., Friese, O. V., Powers, T. W., Agbandje-McKenna, M., Heck, A. J. R. Abstract: Adeno-associated viruses (AAVs) are small, non-enveloped, and have a T=1 icosahedral capsid. They belong to the Parvoviridae, genus Dependoparvovirus. Interest in AAVs has grown over recent years as they have emerged as promising gene therapy vectors. The AAV capsid, encapsulating the transgene, consists, in total, of 60 subunits made up from three distinct viral proteins (VPs) originating from the same cap gene (VP1, VP2, and VP3), which vary only in their N-terminus. While all three VPs play a crucial and specific role in cell-entry and transduction, their exact stoichiometry and organization in AAV capsids has, despite the availability of several high-resolution structures remained elusive. Here we obtained a set of native mass spectra of intact AAV capsids (Mw {approx} 3.8 MDa) that display both highly resolved regions and regions wherein interferences occur. Through spectrum simulation we resolved and elucidated this spectral complexity, allowing us to directly assess the VP stoichiometries in a panel of serotypes from different production platforms. The data reveals an extremely heterogeneous population of capsids of variable composition. The relative abundance for each of the hundreds of co-occurring capsid compositions is accurately described by a model based upon stochastic assembly from a mixed pool of expressed VP1, VP2, and VP3. We show that even the single-most abundant VP stoichiometry represents only a few percent of the total AAV population. We estimate that virtually every AAV capsid in a particular preparation has a unique composition and arrangement, i.e. no particle is identical. The systematic scoring of the stochastic assembly model against experimental high-resolution native MS data offers a sensitive and accurate new method to characterize these exceptionally heterogeneous gene-delivery vectors. Copy rights belong to original authors. Visit the link for more info
HELLOOOO beautiful listeners and welcome back to another ep of Let's Talk, Period.This week, Isabella sat down with Victoria Spiliopoulous, Founder and Principal Instructor at Vicalates. In the midst of COVID-19, Vic, like everyone else, found her plans dramatically changed! What started out as fun online pilates classes with friends during lockdown, pivoted into a business idea. Having launched just one month ago, Vicalates is a boutique, full service Reformer Pilates studio that culminates the principles of Pilates with art, design and sensory experience. She is passionate about women's health, love all bodies and love making all bodies feel good. We talk on her relationship with health and fitness, how she wasn't always into pilates and what led her to take classes, then go onto teach the method, her top tips if you're new to reformer and how to not feel completely overwhelmed, and how you can work to include pilates as a form of movement when you have a chronic condition. Vic is an absolute pocket rocket and is so passionate and driven and just exudes so much light and energy in this chat, and we know you'll leave it feeling uplifted and ready to take on the day!If you loved our chat with Vic and want more from Vicalates, you can find her on Instagram @vicalates or you can learn more and book a class via www.vicalates.com. If you want to keep up with what we're up to you can follow us on Instagram at @letstalkperiodau. We would also love it if you subscribed or followed the podcast, as it helps other listeners to find our show! We also have our very own Let's Talk Period. Podcast Community, which allows you to find like minded listeners and continue the conversation about each and every ep, you can join here.Your host is Isabella Gosling (i_gosling)
In this week's episode, we are joined once again by the insightful Dr Melissa Cameron. In Australia, Endometriosis affects 1 in 9 women. The condition is crippling and as we discovered it is not always easy to diagnose. Dr Melissa explains in detail the condition and how it may affect your fertility.We touch on Adenomyosis, another uterine inflammatory condition, which is when the cells exist or grow into the uterine wall. Women who suffer with Endometriosis often also have Adenomyosis - who knew!!And finally we chat about about Fibroids and discover not all fibroids are dangerous but need to be managed should it compromise you fertility.We hope you enjoy this episode!
Ein erbsengroßes Organ mit wichtigen Funktionen. Frank und Bijan beleuchten die Adeno- und Neurohypophyse genauer.
Podcast 6 of Lost in Menstruation: Adenomyosis & Toxins This episode continues the series of podcasts to recognise Adenomyosis awareness month. This podcast looks at how toxins in and around our environment affect our hormones and symptoms of Adeno. This podcast is brought to you by The Well Woman Project. www.thewellwomanproject.com
Podcast 5 of Lost in Menstruation: Adenomyosis & Herbs This episode continues the series of podcasts to recognise Adenomyosis awareness month. This podcast looks at how herbs can help with the symptoms of Adeno. This podcast is brought to you by The Well Woman Project. www.thewellwomanproject.com
Podcast 4 of Lost in Menstruation: Adenomyosis This episode is all about Adenomyosis in celebration of Adeno awareness month. What is it? What are the symptoms and what can you do to treat it. This podcast is brought to you by The Well Woman Project. www.thewellwomanproject.com
Nase zu und jetzt auch noch die Nebenhöhlen entzündet. Was hilft da? Sind das alles harmlose Mittel, nur weil man sie ohne Rezept bekommt? Heute Teil 1 einer Mini-Serie mit vielen praktischen Tipps für die Erkältungszeit. Wie lange Dauer Schnupfen? Wie Schnupfen bekämpfen? Wie bekomme ich Schnupfen; wie stecke ich mich an? Welches Medikament bei Schnupfen? Inhalt: Wieder VirenVorbeugungSchnäuzen oder Hochziehen?BabiesNasenduscheInhalierenSprays± Konservierungsmittel?SalzZusätze zur Pflege/Schutz der SchleimhautAbschwellendMentholXylomethazolinArzneimittelschnupfenSuchtKnorpelschädigungStinknaseEntzugCortison-haltige NasensprayEinnehmenPflanzliche ExtraktePseudoephedrinNicht bei BluthochdruckKombimittelZusammenfassung:Pharma-Song: //Nächste Woche:Mehr Infos: //Meine Bitte an Sie: //Belege Wieder VirenMehr als 200 Virentypen kommen für eine Erkältung infrage. Meist (40%) Rhinoviren. Daneben Corona-, Parainfluenza-, Respiratory-syncytial-, Adeno- und Rheoviren. Bakterien selten, schleichen sich ein, wenn die Viren erst einmal die Abwehrkräfte geschwächt haben, oder Schleimhäute durch Mißbrauch von Spray geschädigt. Übertragungsweg: Tröpfchen- oder Schmierinfektion Inkubationszeit: 48 bis 72 Stunden Dauer: 7 bis 9 Tage Vorbeugung Händewaschen Hände desinfizieren (kleines Alkoholfläschchen) Echinacea/Sonnenhut, z.B. Meditonsin wirkungslos (Linde et al. 2006) Schnäuzen oder Hochziehen?Schnäuzen (Sommer et al. 2014) natürlicher, effizienter, kein zusätzliches Risiko für Nasennebenhöhlen Papiertaschentuch nur 1 mal. Niesen und Husten in die linke Ellenbeuge, nicht in Hand, schon gar nicht die rechte https://youtu.be/izriQamkh_8 BabiesTropfen (Rhinomer® babysanft, Olynth@ salin) oder oder physiologische Kochsalzlösung in jedes Nasenloch Watte zwirbeln, in die Nase 1 cm reindrehen, Schnodder hängt dran Keine Wattestäbchen - generell nicht Nasenduschev.a. zur Vorbeugung, auch in Allergiezeit zwei Salzstärken, nicht selber mischen isoton: reinigend hyperton. abschwellend Welche? Testsieger Emser®; Fitne, auch OK; Pari, Fränkel aus Glas nicht https://youtu.be/VEttWaqXIxc Inhalierenv.a. bei Nebenhöhlenentzündung Topf mit Heißwasser, ätherische Öle rein Befeuchtend, abschwellend Sprays± Konservierungsmittel?mit billiger ohne teurer -warum? erfordern Spezialgefäße und Pumpvorrichtungen gg. Keime reizen Schleimhäute weniger. Salzisoton = reinigend hyperton = zieht Wasser, schwillt ab, Emser® Nasenspray hyperton + Glycerol = noch stärker abschwellend, bei Nasennebenhöhlenentzündung, z.B. Emser@ sinusitis Gerbstoff-haltige Extrakte aus Grüntee, Heidelbeere, Cranberry, schwarzem Holunder Zusätze zur Pflege/Schutz der SchleimhautAloe Dexpanthenol Ectoin = Film-bildend Hyaluronsäure = befeuchtend AbschwellendMenthol andere ätherische Öle XylomethazolinVerengt Blutgefäße: Erwünscht Sekret raus danach Nase freier Schleimhaut Schwellung nimmt über längere Zeit ab Unerwünscht Durchblutung sinkt Blutdruck kann steigen Abhängigkeit Arzneimittelschnupfen>7 Tage, mehrmals täglich Schleimhäute gewöhnen sich an regelmäßige Dosis "Rebound": Wirkung lässt nach, Nasenschleimhäute schwellen schlimmer als vorher! Sprüht wieder, und wieder. Sucht Männer häufiger oft zusätzliches Problem der Atmung, z.B. schiefe Nasenscheidewand. Schämen sich, gehen nicht zum Arzt, über viele Jahre... KnorpelschädigungDurch Verengung der Blutgefäße, verringerte Durchblutung der Nase und Nasenknorpel. Knorpelgewebe stirbt ab: Loch in Nasenscheidewand, Nasenrücken sackt ein (Sattelnase) Schäden zum Teil nicht heilbar StinknaseSchleimhäute trocknen aus, kleine Risse, regelmäßig Nasenbluten und Krusten in der Nase. Keimbefall, im extrem "Stinknase", d.h. fauliger Geruch, den der Betroffene selbst gar nicht bemerkt, sein Umfeld allerdings sehr. Zwar selten, aber nicht mehr rückgängig zu machen. EntzugEntw...
V Sessions with Yves V - a discovery in electronic music as told by one of the dance scene's most exciting DJ and Producer stars - Yves V! Explore new sounds and the most upfront club beats from Belgium's number 55 DJ in the World according to the official Top 100 DJ Poll. V Sessions presented to you each and every week by Yves V. 01. Simioli & Benny Camaro - Stardust (Original Mix) 02. Redondo X First Day - Burnin Up (Extended Mix) 03. Toby Green - Lift Me Up (Original Mix) 04. Daddy's Groove - Basement (Extended Mix) 05. Jay Hardway - Need It 06. Sagan & Boostereo - So Real (Extended Mix) 07. Tom Staar & Gordon Edge - Itsa Trumpet Thing (Extended Mix) 08. Yves V & Marc Benjamin - Blow 09. MAD M.A.C. vs Jamis - Renegade Master (Dimitri Vegas & Like Mike Edit) 10. Radiology & FTKS - Helium (feat. Thomas Daniel) 11. Mogsba & Aitor Blond X Bassriv - Pressure 12. J-Trick X Tom Budin - Heard Right 13. ADENO & RAGG & Hypnotune - Far Away CLASSIC OF THE WEEK 14. Paul Kalkbrenner - Sky and Sand
Knowing the histology and embryology of the anorectal junction helps you to understand why you should band piles above the dentate line, why cancers in the region have different tissues of origin and spread to different lymph nodes. In this video podcast Susan Anderson takes you though important histological features of the large bowel and contrasts them with the different features of the anal canal. Clinical application of these features is also described Dr Susan Anderson is Associate Professor in Pathology at the University of Nottingham, UK
Mauro Giacca, ICGEB, Molecular Medicine, Group Leader, Trieste - ITALY speaks on "Adeno-associated virus (AAV)-based vectors as powerful tools for gene transfer into post-mitotic cells in vivo". This seminar has been recorded at ICTP Trieste by ICGEB Trieste
Mauro Giacca, ICGEB, Molecular Medicine, Group Leader, Trieste - ITALY speaks on "Adeno-associated virus (AAV)-based vectors as powerful tools for gene transfer into post-mitotic cells in vivo". This seminar has been recorded at ICTP Trieste by ICGEB Trieste
Medizinische Fakultät - Digitale Hochschulschriften der LMU - Teil 15/19
Jedes Jahr erleiden weltweit circa 22 Menschen pro eine Million Einwohner eine Querschnittslähmung, die bei den Betroffenen zu dauerhaften Behinderungen und erheblichen Einschränkungen im Alltag führt. Die schwerwiegenden Defizite nach einer Querschnittslähmung, darunter Lähmungen und chronischer Schmerz, sind darauf zurückzuführen, dass geschädigte Axone im Rückenmark kaum regenerieren und es auch nur in geringem Ausmaß zur funktionellen Reorganisation der noch erhaltenen Nervenverbindungen kommt. Im Unterschied zum peripheren Nervensystem, wo zerstörte Nervenfasern erfolgreich regenerieren, ist die axonale Regenerationskapazität des zentralen Nervensystems (ZNS) spärlich ausgeprägt. Zwar konnte durch intensive Forschung im Verlauf der letzten Jahrzehnte eine Anzahl von „extrinsischen“ wachstumshemmenden Molekülen von Gliazellen und der extrazellulären Matrix des ZNS identifiziert werden. Es gibt jedoch zunehmend Hinweise darauf, dass zahlreiche dieser „extrinsischen“ Signale letztlich in „intrinsische“ Signalwege der Neuronen selbst einmünden um schließlich die Transkription neuronaler Gene zu verändern. Einer der interessantesten intrinsischen Regulatoren axonaler Regeneration ist der Transkriptionsfaktor ´Signal transducer and activator of transcription 3´ (STAT3). In dieser Arbeit habe ich mithilfe moderner In-vivo-Mikroskopie sowie viraler Gentherapie in Spinalganglien genetisch veränderter Mäuse zum ersten Mal die entscheidende Rolle von STAT3 in der intrinsischen Regulation axonaler Regeneration in vivo identifizieren können. So konnte nachgewiesen werden, dass die nur rudimentär ausgeprägte Regeneration der zentralen Fortsätze der Neuronen in den Spinalganglien mit einer fehlenden Induktion von STAT3 in den entsprechenden Ganglien einhergeht. Durch Überexpression von STAT3 mittels rekombinanter Adeno-assoziierter Viren in zervikalen Spinalganglien konnte zwei Tage nach Läsion das Auswachsen von Axonen sowie das Aussprießen von Kollateralen um mehr als das Vierfache gesteigert werden. Darüber hinaus konnte mittels repetitiver Multiphotonenmikroskopie einzelner fluoreszenzmarkierter Axone gezeigt werden, dass die Überexpression von STAT3 nur in der Frühphase (2-4 Tage) die axonale Wachstumsgeschwindigkeit erhöhen konnte, nicht aber zu einem späteren Zeitpunkt (4-10 Tage) nach Läsion. Um die Hypothese zu überprüfen, dass die fehlende Aufrechterhaltung des axonalen Wachstums durch Kontakt der aussprossenden Axone mit einem zunehmend inhibitorischen ZNS-Milieu bedingt ist, wurde die Überexpression von STAT3 zusätzlich mit der Applikation von Chondroitinase ABC, einem Enzym, das die inhibitorischen Moleküle der glialen Narbe neutralisieren kann, kombiniert. Dabei konnte ich zeigen, dass das durchschnittliche Wachstum von Axonen um mehr als das Zweifache gesteigert werden konnte. Aus den Ergebnissen meiner Versuche konnte ich mehrere Schlussfolgerungen ziehen: Erstens konnte ich STAT3 als effektiven Initiator axonalen Wachstums nach Rückenmarksläsion identifizieren. Zweitens wurde nachgewiesen, dass STAT3 selektiv Wachstum in der frühen Phase reguliert, nicht jedoch zu späteren Zeitpunkten. Daraus folgt, dass das axonale Regenerationsprogramm aus mindestens zwei verschiedenen, molekular distinkten Phasen besteht. Mit STAT3 wurde zum ersten Mal ein phasenspezifischer Regulator der axonalen Regeneration entdeckt. Abschließend konnte gezeigt werden, dass synergistische Therapien - wie hier durch die Kombination von STAT3 und Chondroitinase ABC belegt wurde - axonales Wachstum zusätzlich verbessern. Die gewonnenen Einblicke in die Mechanismen axonaler Regeneration geben Grund zur Hoffnung, dass in der Zukunft effektive Kombinationstherapien für Querschnittsgelähmte entwickelt werden können.
Hosts: Vincent Racaniello, Rich Condit, Alan Dove, and Kathy Spindler The TWiVerers answer listener email about genetically modified chickens, a hendra vaccine for horses, online education, curing color blindness, Roosevelt and polio, Th cells, and much more. Links for this episode: TWiV 116: Cocaine, colonies, and chickens Glofish Recombinant Hendra vaccine Gene therapy for color blindness (Nature) FDR, polio, and Guillain-Barré Transcript of TWiV 197: Philip Marcus (pdf) TWiV 10: Bats, elephants, and AIDS TWiM 6: Phage therapy TWiP 47: For whom the trich tolls Viruses of protozoan parasites (virology blog) Long in the tooth Transcript of 'How to read a science paper' (pdf) FEMA disaster preparedness courses Letters read on TWiV 212 Weekly Science Picks Rich - OverviewAlan - Notes towards the complete works of ShakespeareKathy - Correlation vs. Causation (#1, #2, #3)Vincent - Periodically inspired Listener Pick of the Week Mark - Life of a Nature paperRicardo - Things don't go viral Send your virology questions and comments (email or mp3 file) to twiv@twiv.tv
Medizinische Fakultät - Digitale Hochschulschriften der LMU - Teil 08/19
Bei der Tumorangiogenese ist die Balance zwischen den pro- und antiangiogenen Faktoren zu Gunsten der proangiogenen Faktoren hin verschoben. Therapeutisch lässt sich die Tumorangiogenese durch eine Hemmung proangiogener Faktoren wie VEGF auch im klinischen Setting wirksam beeinflussen. In präklinischen Modellen ließ sich zeigen, dass auch durch Gabe von physiologisch vorkommenden antiangiogenen Faktoren wie Endostatin und Angiostatin das Wachstum experimenteller Tumoren signifikant gehemmt werden konnte. Angiostatin besteht aus den ersten Kringel-Domänen des Plasminogens und wird bei einer Reihe von physiologischen Prozessen im Körper durch proteolytische Spaltung freigesetzt. Es inhibiert primäres und metastatisches Tumorwachstum durch Hemmung der Tumorneoangiogenese. Da diese löslichen Faktoren eine sehr kurze Halbwertszeit aufweisen, ist eine Gabe als Protein wenig erfolgversprechend und erste klinische Daten zur Applikation von Endostatin als Protein in klinischen Studien waren enttäuschend. Ein effizienter alternativer Applikationsweg für diese Faktoren stellt zweifellos eine gentherapeutisch vermittelte systemische Überexpression dar, wie sie beispielsweise bei Gerinnungsfaktoren bereits in ersten klinischen Studien angewendet worden ist. Sowohl die Leber als auch die Muskulatur können dabei als Orte der Überexpression nach Gentransfer genutzt werden. Der Wahl und Optimierung des Vektorsystems kommt bei einer solchen Strategie ein zentraler Stellenwert zu. In der hier vorgelegten Arbeit wurde ein Vektorsystem basierend auf Adeno-assoziierten Viren (AAV) für die antiangiogene Gentherapie entwickelt und optimiert. Konventionelle AAV-Vektoren basieren auf einem einzelsträngigen DNA Genom, welches von infizierten Zellen zuerst in ein doppelsträngiges Genom umgewandelt werden muss, um eine Genexpression zu ermöglichen. Dieser Schritt ist limitierend auf dem Weg zur Transgenexpression. In dieser Arbeit wurde ein sogennanter „self compementary“ AAV-Vektor (scAAV) hergestellt und charakterisiert, der in der Zielzelle primär eine doppelsträngige DNA zur Verfügung stellt. Die Strategie beruhte dabei auf Daten der Arbeitsgruppe von Prof. Dr. J. Samulski, Capel Hill, USA. Es wurde auf dieser Basis ein AAV-Konstrukt zur Expression des Green-Fluorescent Protein (GFP) als Markergen und ein weiteres Konstrukt zur Expression von Angiostatin kloniert und in einem AAV-Serotyp 2 verpackt. Das scAAV-Vektorsystem zeigte in vitro eine um eine log-Stufe stärkere Genexpression (GFP) als konventionelle AAV-Vektoren. Damit wurden die Daten der amerikanischen Arbeitsgruppe bestätigt. In funktionellen in-vitro-Experimenten zeigten sich die scAAV/Angiostatin-Vektoren den konventionellen AAV/Angiostatin-Vektoren signifikant überlegen bei der Hemmung der Proliferation von Endothelzellen. In der Zusammenfassung konnte im Rahmen dieser Arbeit der Grundstein gelegt werden für die Anwendung von scAAV zur Expression von Angiostatin im Rahmen der Gentherapie von Tumoren.
Fakultät für Chemie und Pharmazie - Digitale Hochschulschriften der LMU - Teil 02/06
Fri, 6 Jul 2007 12:00:00 +0100 https://edoc.ub.uni-muenchen.de/7095/ https://edoc.ub.uni-muenchen.de/7095/1/Gerner_Franz.pdf Gerner, Franz ddc:540, ddc:500, Fakultät für Chemie und
Medizinische Fakultät - Digitale Hochschulschriften der LMU - Teil 06/19
Gentherapie ist ein vielversprechender neuer Ansatz für die Tumortherapie. Daher ist die Entwicklung eines effizienten Vektorsystems von großer Bedeutung. Bisher wurden unterschiedliche Serotypen des Adeno-assoziierten Virus (AAV) beschrieben, welche einen erheblichen Unterschied im Tropismus für bestimmte Gewebearten und Zelltypen aufweisen. Daraufhin haben wir systematisch den effizientesten Serotyp unter den AAV Serotypen 1 bis 5 bezüglich der Effektivität des Gentransfers in humanen Tumorzellen untereinander verglichen. Um alle Einflüsse außer denen, die auf das Kapsid zurückzuführen sind, auszuschließen, enthalten alle fünf Serotypen die gleiche Transgen-Kassette, einheitlich flankiert von der ITR (Invertierte terminale Wiederholung = inverted terminal repeat) des AAV-Serotyp 2. AAV2 war der effizienteste Serotyp in einer Reihe klinisch relevanter Tumorzelllinien mit einer Transduktionseffizienz von über 99,5±0,2 % bei nur 1000 genomische Partikeln / Zelle. Transduktionseffizienzen um die 70 % konnte durch den Serotyp 1 in Prostata- und Zervixkarzinom und durch den Serotyp 3 in Prostata-, Mamma-, Kolon- und Zervixkarzinom beim Einsatz von 1000 genomischen Partikeln pro Zelle erzielt werden. AAV4 und AAV5 haben durchgehend schlecht transduziert. Die höchste Transduktionseffizienz unter den humanen Tumorzelllinien betrug für AAV4, 40,6±3,1 % und 25,4±2,2 % für AAV5 beim Zervixkarzinom. Die jüngsten Fortschritte in der AAV-Vektor-Technologie weisen darauf hin, dass AAV- basierte Vektoren für die Tumorgentherapie eingesetzt werden können. Unsere Vergleichsanalysen zeigen, dass AAV2 zwar der am vielversprechenste Kandidat für eine solche Anwendung ist, aber AAV1 und AAV3 auch als gute Alternativen verwendet werden können. Dies ist besonders dann von Bedeutung, wenn eine Anwendung mit AAV2 durch neutralisierende Antikörper verhindert wird. Gao et al. konnten zeigen, dass diese Serotypen trotz des Vorhandensein neutralisierender Antikörper gegen AAV2 zum effizienten Gentransfer befähigt sind. Die Transduktionseffizienz von AAV4 und AAV5 ist generell zu niedrig, was eine effiziente Anwendung in der Tumorgentherapie derzeit unmöglich macht. Bei Untersuchungen einiger muriner Zelllinien stellten wir fest, dass sie sich am besten von AAV1 transduzieren lassen. Um nachzuweisen, ob AAV1 generell murine Zellen besser transduziert als AAV2, müssten weitere Untesuchungen durchgeführt werden. Dies ist für die zukünftige AAV-Forschung von Bedeutung, da eine Bestätigung unserer Beobachtung bedeuten würde, dass die Ergebnisse aus den zahlreichen in-vivo-Experimenten mit Mäusen nicht auf den Menschen übertragbar wären.
Medizinische Fakultät - Digitale Hochschulschriften der LMU - Teil 06/19
Tumorerkrankungen stellen die zweithäufigste Todesursache in den Industrieländern nach den kardiovaskulären Erkrankungen dar. Trotz moderner Therapien verlaufen diese Erkrankungen vor allem im fortgeschrittenen Stadium immer noch häufig letal. Es besteht also Bedarf neue, innovative Therapieansätze zu verfolgen und zu optimieren. Die Gentherapie ermöglicht die Umsetzung attraktiver Strategien zur Behandlung von Tumorerkrankungen. Solche Strategien basieren entweder auf einem Gentransfer in Tumorzellen mit dem Ziel diese so zu modifizieren, dass sich daraus ein anti-Tumor Effekt ergibt (Überexpression immunmodulatorischer Faktoren, Suizidgene), oder auf der systemischen Überexpression solubler Faktoren, die zu einer Hemmung des Tumorwachstums führen (z. B. antiangiogene Faktoren). Solche Ansätze konnten in jüngster Zeit erfolgreich in Tiermodellen umgesetzt werden. Ergebnisse aus klinischen Studien sind demgegenüber bislang enttäuschend ausgefallen. Limitationen der verwendeten Vektorsysteme werden dafür verantwortlich gemacht. Daher ist die weitere Optimierung der Vektorsysteme von entscheidender Bedeutung. Die vorliegende Arbeit beschäftigt sich mit der Optimierung des Tumor-Gentransfers in soliden Tumoren basierend auf dem Adeno-assoziierten Virus (AAV). AAV ist ein einzelsträngiges DNS-Virus. Auf dem Weg zur Transgen-Expression stellt die Doppelstrangsynthese einen wesentlichen limitierenden Schritt dar. In dieser Arbeit wurden modifizierte AAV-Vektoren, die primär eine doppelsträngige DNS zur Verfügung stellen, im Hinblick auf die Effizienz des Tumor-Gentransfers unter in vitro- Bedingungen systematisch untersucht. Es wurden dazu AAV-Vektoren hergestellt, die primär eine doppelsträngige DNS zur Verfügung stellen. Es konnte gezeigt werden, dass bei Verwendung von doppelsträngigem AAV (dsAAV), bei dem etwa 10 % der Vektoren einer Präparation doppelsträngige DNS aufweisen, die Transduktionsrate in soliden Tumorzelllinien bis auf das 4-fache erhöht werden kann. Durch die Verwendung eines self-complementary AAV (scAAV) Vektors, bei den in über 90 % Viren generiert werden, die eine doppelsträngige DNS aufweisen, konnte die Transduktionsrate weiter bis auf das bis zu 17-fache gegenüber konventionellen einzelsträngigen AAV gesteigert werden. Der Abbau von AAV über Proteasomen wurde in Epithelien der Atemwege als ein Faktor charakterisiert, der für eine Verminderung der Gentransfer-Effizienz verantwortlich ist. In dieser Arbeit konnte durch Einsatz eines Proteasomen-Inhibitors (MG132) gezeigt werden, dass dieser Mechanismus auch für den Gentransfer in Tumorzellen eine wichtige Rolle spielt. Dies trifft vor allem für die Tumorzelllinien zu, die durch MG132 nicht in die Apoptose getrieben werden. In vitro konnte somit durch kombinierte Verwendung von scAAV sowie MG132 der Tumor-Gentransfer in bestimmten Zelllinien -wie zum Beispiel in der Kolonkarzinom-Zelllinie HT29 um den Faktor 20- verbessert werden. Bei der Anwendung der modifizierten AAV-Vektoren in einem HeLa-SCID-Mausmodell zeigte sich aber eine deutliche Abnahme der Gentransfer-Effizienz unter in vivo-Bedingungen. In vergleichenden Experimente an Tumor-Spheroiden von HeLa-Zellen und einer humanen Neuroblastom-Zelllinie wurde herausgearbeitet, dass die extrazelluläre Matrix (ECM) eine hemmende Rolle beim AAV-vermittelten Gentransfers in HeLa-Spheroide ausübt, während sie beim Gentransfer in Tumoren neuronalen Ursprungs (Neuroblastom) signifikant geringer ausfällt. Um AAV als Vektor für den in vivo Tumor-Gentransfer einsetzen zu können, müssen Strategien gefunden werden, um die Barriere, die durch die extrazelluläre Matrix gegeben ist, zu überwinden. Ein Targeting der Vektoren, das heißt, eine gezielte Veränderung des natürlichen Tropismus der Viren, stellt dazu einen attraktiven Lösungsansatz dar.
Fakultät für Chemie und Pharmazie - Digitale Hochschulschriften der LMU - Teil 02/06
Tue, 23 May 2006 12:00:00 +0100 https://edoc.ub.uni-muenchen.de/7345/ https://edoc.ub.uni-muenchen.de/7345/1/Goldnau_Daniela.pdf Goldnau, Daniela ddc:540, ddc:500, Fakultät für Chemie
Fakultät für Chemie und Pharmazie - Digitale Hochschulschriften der LMU - Teil 02/06
Tue, 23 May 2006 12:00:00 +0100 https://edoc.ub.uni-muenchen.de/8690/ https://edoc.ub.uni-muenchen.de/8690/1/Lux_Kerstin.pdf Lux, Kerstin ddc:500, ddc:540, Fakultät für Che
Fakultät für Chemie und Pharmazie - Digitale Hochschulschriften der LMU - Teil 02/06
Despite promising advance in the development of viral vectors based on AAV for human gene therapy, several major hurdles for a more general use remain. Among these, efficient in vivo applications are limited by the high prevalence of neutralizing antibodies in the human population, which can reduce or eliminate transgene expression. A successful prevention of antibody-mediated vector neutralisation requires the modification of specific epitopes of the viral capsid responsible for Ab binding. The aim of this work was to demonstrate that immune-escaping capsid variants can be generated through genetic modifications of the virus by taking advantage of combinatorial engineering and directed evolution protocols. A library of 107 AAV mutants carrying random point mutations scattered throughout the capsid gene of AAV was created by error prone PCR and screened for clones that were able to avoid neutralization by AAV-neutralizing human sera. Three mutants carrying the mutations R459G, R459K and N551D respectively and a double mutant with a combined R459K/N551D mutation were strongly enriched after the selection procedure. Characterisation of these clones showed an immune-escaping phenotype for all mutants. However, the combination mutant proved to be superior in both evasion of neutralization and infectivity, leading to the assumption that multiple mutations convey enhanced effects. Therefore, the remaining pool was subjected to DNA shuffling and additional error prone PCR, yielding a second-generation library, which was screened for further improved phenotypes. In this context, a method which we called evolution monitoring was devised allowing optimization of several experimental conditions that are typically critical for successful outcome of library panning. These refinements yielded novel variants with further enhanced immune-escape abilities and infectivity in comparison to previously selected mutants. Finally, obtained data suggests an enormous potential for using the here developed tools to study infection biology of viruses by reverse genetics. This work showed for the first time that error prone PCR and DNA shuffling can be successfully applied for genetic engineering of a virus by a directed evolution approach. In principle, using appropriate selection protocols these techniques should be adaptable for addressing a wide variety of challenges concerning AAV in particular and virology in general.
The development of safe and efficient gene transfer vectors is crucial for the success of gene therapy trials. A viral vector system promising to meet these requirements is based on the apathogenic adeno-associated virus (AAV-2), a member of the parvovirus family. The advantages of this vector system is the stability of the viral capsid, the low immunogenicity, the ability to transduce both dividing and non-dividing cells, the potential to integrate site specifically and to achieve long-term gene expression even in vivo, and its broad tropism allowing the efficient transduction of diverse organs including the skin. All this makes AAV-2 attractive and efficient for in vitro gene transfer and local injection in vivo. This review covers the progress made in AAV vector technology including the development of AAV vectors based on other serotypes, summarizes the results obtained by AAV targeting vectors and outlines potential applications in the field of cutaneous gene therapy. Copyright (C) 2004 S. Karger AG, Basel.
Fakultät für Chemie und Pharmazie - Digitale Hochschulschriften der LMU - Teil 01/06
Thu, 30 Oct 2003 12:00:00 +0100 https://edoc.ub.uni-muenchen.de/1584/ https://edoc.ub.uni-muenchen.de/1584/1/Perabo_Luca.pdf Perabò, Luca ddc:540, ddc:500, Fakultät für Chemie und Pharmazie
Fakultät für Chemie und Pharmazie - Digitale Hochschulschriften der LMU - Teil 01/06
Vectors based on adeno-associated virus type 2 (AAV) offer considerable promise for somatic gene therapy of various diseases (e.g. cystic fibrosis, hemophilia B, cancer). Limitations, however, still exist and require further improvement. The study presented here addresses two major problems that hamper a widespread use of AAV in human gene therapy: First, the loss of site-specific integration of recombinant AAV vectors (rAAV) due to the deletion of the rep gene, and secondly, the potential neutralization of AAV gene therapy vectors by preexisting antibodies. It could be demonstrated that site-specific integration of a transgene encoding rAAV vector can be efficiently restored by providing rep as plasmid DNA in trans. Based on these findings, a rAAV vector was developed where a plasmid coding for Rep was coupled as polylysine/DNA complex (PLL/DNA) directly to the capsid of the virion and co-transduction of such a PLL/DNA coupled to AAV was shown. Thus, providing rep-DNA as PLL/DNA should allow rAAV vectors to integrate specifically at chromosome 19. To characterize immunogenic domains of the AAV capsid and to develop strategies to circumvent neutralization by antibodies, AAV capsid mutants carrying peptide insertions in surface exposed loop regions were investigated in binding and neutralization assays. Three positions could be identified in the AAV capsid (at aa 534, 573, and 578 of the VP1 protein) where binding and neutralization of the virus by human serum samples was markedly reduced. These result suggest that capsid modifications could help to overcome binding and neutralization by human antisera in clinical gene therapy applications.
Fakultät für Chemie und Pharmazie - Digitale Hochschulschriften der LMU - Teil 01/06
Mon, 26 Mar 2001 12:00:00 +0100 https://edoc.ub.uni-muenchen.de/367/ https://edoc.ub.uni-muenchen.de/367/1/Seisenberger_Georg.pdf Seisenberger, Georg